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PTEN and TP53 loss are common molecular alterations in aggressive prostate 
cancer that progresses to castrate resistant prostate cancer (CRPC).  PTEN/TP53 loss 
contributes to regulation of self-renewal and differentiation in prostate progenitor cells, 
the presumptive tumor and metastasis initiating cells for prostate cancer.  TP53 plays an 
important role in regulating normal cellular metabolism, and loss of function is 
responsible for metabolic alterations in tumor cells, including increased aerobic 
glycolysis.  We use a novel model of Pten/Tp53 deleted prostate cancer to investigate 
properties of tumor and metastasis initiating cells, and metabolic alterations that 
contribute to the evolution of CRPC. 





cancer to develop an orthotopic model derived from a clonal cell line from the parental 
heterogeneous prostate carcinoma.  We used histopathology and immunohistochemistry 
to characterize the orthotopic primary tumors and metastases.  We performed 
metabolomic screening followed by focused analysis of HK II enzyme levels, activity, 
  
and cellular distribution in androgen replete and androgen deprived tumors.  We also 
compared HK II levels in primary and metastatic human prostate cancer. 
Tumor heterogeneity was due to transformation of tumor and metastasis initiating 
cells with biphenotypic potential capable of basal and luminal differentiation.  There was 
epithelial-to-mesenchymal transition (EMT) in cells of the luminal lineage.  The model 
was capable of androgen independent growth, which influenced the differentiation of 
metastasis initiating cells.  CRPC had increased reliance on glycolysis with increased 
cytoplasmic and mitochondrial-associated HK II.  These metabolic adaptations afforded 
CRPC increased ability to withstand metabolic stress.  HK II levels in human metastases 
were markedly increased compared to primary tumors.   
Pten/Tp53 loss in prostate cancer contributes to lineage plasticity in both tumor 
and metastasis initiating cells, contributing to heterogeneity observed in primary tumors 
and metastases. Increased glycolysis due to increased total and mitochondrial HK II is a 
metabolic adaptation that contributes to the evolution of aggressive disease, with 
progression to androgen independence, providing increased energy and carbon precursors 
for anabolic processes.  Mitochondrial bound HK II blocks apoptosis and contributes to 
survival in the androgen deprived environment.  Targeting this metabolic adaptation may 
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Chapter 1: Introduction 
I. Introduction to prostate cancer 
A. Epidemiology 
Prostate cancer is the second leading cause of cancer-related deaths in males, with 
approximately 1 in 6 males in the USA becoming affected [1, 2].  Prostate cancer will 
cause an estimated 29,480 deaths out of 233,000 new cases diagnosed in 2014 in the 
USA which is second only to lung cancer as the leading cause of cancer related deaths in 
men with an estimated 159,260 deaths out of an estimated 224,210 cases in 2014 [3]. 
Metastatic castrate resistant disease is usually the cause of death in these patients, as the 
primary tumors can be removed with surgical prostatectomy.  The most common site of 
prostate metastasis is bone, with approximately 84% of patients presenting with 
metastasis having bone metastases followed by distant lymph nodes (10.6%), liver 
(10.2%), and thorax (9.1%) [4].  The development of mouse models that recapitulate the 
important features of progression to castrate resistant prostate cancer (CRPC) and 
metastasis are of paramount importance for the mechanistic study of this disease.  This 
dissertation research describes the development of a novel mouse model of CRPC that is 
used to investigate the identity of tumor and metastasis initiating cells, and the metabolic 
changes that provide adaptation for the growth and survival of prostate cancer cells in the 






B. Pathogenesis of human prostate cancer 
Human prostate cancer usually follows a predictable pattern of initial prostatic 
intraepithelial neoplasia (PIN) with a slow progression to invasive carcinoma that can 
take up to 10 years, and in some cases the development of metastasis.  In the early stages 
the tumors are usually androgen dependent yet progress to androgen independence with 
the development of  invasive carcinoma and metastasis [5].  There has been intensive 
research into the molecular pathogenesis and genomics of prostate cancer.  Many tumor 
suppressor genes have been implicated based on the region of chromosomal deletions in 
human prostate cancer specimens (ie: RB, TP53, PTEN, and NKX3.1).  PTEN  loss is 
often seen early (initiation), while p53 loss is often late in disease progression [6, 7].  
PTEN deletions/mutations have been detected in 30% of primary and 64% of metastatic 
prostate carcinomas [8-10].  
C. Signaling pathways driving progression in prostate cancer 
Two of the major signaling pathway networks that have been implicated in 
driving human prostate cancer progression to castrate resistant prostate cancer (CRPC) 
are the AKT/mammalian target of Rapamycin (AKT/mTOR) and the ERK/MAPK 
signaling pathways [11].  Using mouse models as well as IHC analysis on human prostate 
cancer TMAs, Kinkade et. al, demonstrated the synergistic effect of the AKT/mTOR and 
the ERK/MAPK pathways in promoting the growth of CRPC [11].   In their 
investigation, p-AKT and p-ERK were elevated in human PIN in 28% and 40% of cases 
respectively, while in high-grade adenocarcinoma p-AKT and p-ERK were elevated in 
79% and 68% of cases respectively.  The mouse model described in this dissertation has 
upregulation of PI3K/AKT/mTOR signaling pathway as a result of Pten deletion, a 
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negative regulator of AKT.  IHC results also have shown high levels of both nuclear and 
cytoplasmic pERK, suggesting that there is also activation of MAPK signaling. 
D. The role of androgen receptor signaling 
The growth of normal prostate epithelial cells, as well as the growth of neoplastic 
prostate cancer cells, is highly dependent upon the androgen receptor (AR) and its 
signaling mechanisms [12].  The first line of treatment in most cases of non-prostate 
confined, or metastatic prostate cancer, is blockage of normal AR signaling. However, in 
a small percentage of men the prostate cancer will adapt to the loss of AR signaling and 
progress to CRPC.  There have been many mechanisms proposed, and confirmed, by 
which prostate cancer cells adapt to maintain androgen signaling networks in the 
presence of minimal castrate levels of circulating androgens [13].   There is a great deal 
known about the effects of androgen stimulation or withdrawal on human prostate cancer 
cells lines in vitro [14-16], and of the mechanisms of escape from androgen deprivation 
in CRPC specimens [12-15, 17, 18].  However, data is lacking regarding the selection 
process by which tumor cells subjected to androgen deprivation therapy eventually adapt 
to survive and proliferate despite the minimal castrate levels of androgens.  In this 
dissertation we describe a novel mouse model which can be used to track the evolution of 
CRPC.  Using this model, we identify that a change in tumor energy metabolism is 
associated with the adaptation of prostate cancer cells to the androgen deprived 
environment.  Mouse models of androgen independent prostate cancer are crucial for 
investigating the effects of androgen withdrawal, as similar studies in humans are 




II. Modeling human prostate cancer in the mouse 
A. Comparison of mouse and human prostate glands  
In humans the prostate gland is an approximately walnut-sized organ which 
surrounds the urethra at the base of the bladder.  Its normal function is the production of 
important secretions for the seminal fluid.  The architecture of the human prostate can be 
divided into a central zone, the transitional zone, and the peripheral zone [19, 20].  The 
outermost peripheral zone is where most prostatic adenocarcinomas arise, while the more 
common benign prostatic hyperplasia arises from the transitional zone.  The mouse 
prostate, in contrast, has a lobular architecture with paired ventral, anterior, and 
dorsolateral lobes.  Each of these lobes have unique patterns of ductal branching, 
epithelial cell histology, gene and protein expression  [21].  Both the mouse and the 
human contain the same three major epithelial cell types: luminal, basal, and 
neuroendocrine cells.  In the human there is a continuous layer of basal cells which 
express CK5 and p63, which support the luminal cells which express CK8/CK18.  Rarely 
in the epithelial cell layer there are synaptophysin + neuroendocrine cells as well.  These 
epithelial cells lie on a basement membrane which is then supported by a large amount of 
fibro vascular stroma.  The mouse, in contrast, does not have a complete basal cell layer, 
and there is only a thin layer of fibro muscular stroma that surrounds each gland.  In the 
human, prostate adenocarcinoma is usually comprised of cells with a luminal 
(CK8/CK18) phenotype.   However, other rare variations include basal cell carcinoma 
and neuroendocrine carcinoma of the prostate.  Thus, when designing/characterizing 
mouse models of prostate cancer, one must pay close attention to the morphological and 
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molecular expression profile of the mouse prostate cancer to ensure its relevance to the 
human disease which we wish to model. 
B. Genetically engineered mouse models of human prostate cancer 
Transgenic mouse models provide the opportunity to study the molecular 
pathogenesis of prostate cancer in a model system with a defined genetic background that 
can be easily manipulated to test mechanistic hypotheses.  The development of relevant 
mouse models of human prostate cancer is critical for the mechanistic study of prostate 
carcinogenesis as the data obtained from human specimens regarding the molecular 
mechanisms of carcinogenesis and metastasis is only correlative.  In addition, there are 
only a limited number of human cancer lines available for study and these are from non-
representative and variable genetic backgrounds.  For example two of the commonly used 
human prostate cancer cell lines, LnCAP and PC3, were isolated from individual tumors 
over 30 years ago.  The LnCAP cell line was isolated from a human prostate cancer 
lymph node metastasis and described in 1983 [22], while the PC3 cell line was isolated 
from a human prostate cancer bone metastasis and described in 1979 [23].  Many studies 
have used these cell lines in both basic and pre-clinical research [24-29].  Clearly 
improvements can be made. 
Many investigations into the molecular pathology of human specimens give 
conflicting results due to tumor heterogeneity/multifocality or gene inactivation by a 
mechanism other than a coding region lesion (ie: promoter methylation, mutations in 
regulatory sequences, etc.) [6, 30].  In addition, the long term in-vitro growth of human 




The ideal mouse model should recapitulate both the human disease phenotype 
(morphology and disease progression) and molecular pathogenesis.  Several transgenic 
mouse models have been developed which to some degree model human prostate 
carcinogenesis (although metastasis in these models is rare).  A review of mouse models 
of prostate cancer was recently published which provides a comprehensive 
histopathological analysis of the most recently developed mouse models of prostate 
cancer [32].  A review of older mouse models of prostate cancer is provided in the 
consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer 
Consortium Prostate Pathology Committee [33]. Prostate specific deletion of Pten driven 
by the rat Cre-Probasin4 (PB-Cre4) transgene has been shown in mice to lead to prostate 
adenocarcinoma that is capable of lymphatic invasion [34]. Chen et. al.[35] deleted both 
Tp53 and Pten in the prostate which led to a more rapid progression to invasive 
adenocarcinoma than with Pten deletion alone, due to the role of Tp53 loss in preventing 
tumor cell senescence. Pten deletions have also been combined with other deletions to 
provide a “second hit” such as with p27
-/- 
[36] , Nkx3.1 [37, 38] , or Smad4 [39]. 
 In our mouse model of prostate cancer described herein, we also used deletion of 
Tp53 and Pten; however we report important findings that were not described in the 
initial description of the model.  We performed a thorough characterization of the 
histopathological progression of the model and describe previously unreported 
heterogeneity in histopathological phenotypes including: adenosquamous carcinoma, 
basal/squamous carcinoma, and sarcomatoid carcinoma [40].  We also demonstrate that 
the sarcomatoid carcinoma arises as a result of epithelial-to-mesenchymal transition 
(EMT) from adenocarcinoma of a luminal cell phenotype.  In addition we also investigate 
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the role of Tp53 loss in regulating the differentiation of tumor cell lineage, and identify 
the tumor and metastasis initiating cell as a bi-potential progenitor capable of 
differentiating along both basal and luminal cell lineages.  
While Tp53 is often thought of as the master regulator of cell cycle progression, 
there has been an increasing realization of the effects of Tp53 in regulating cellular 
metabolism.  Tp53 has been shown to regulate cellular metabolic response to stress and 
the loss of this function has been shown to lead to characteristic features of tumor 
metabolism including increased glycolysis and increased glutaminolysis to fuel tumor 
energy production and anabolic reactions [41-43].  This characteristic tumor metabolic 
phenotype due to loss of Tp53 forms the basis of our investigation into the metabolic 
adaptation of prostate cancer to CRPC.    
C. Orthotopic injection models of prostate cancer 
The utility of employing orthotopic injection to access the normal prostate 
microenvironment for growth and metastasis of injected cells has been demonstrated in 
numerous studies involving a variety of prostate cancer cell lines where growth in the 
subcutaneous tissue or renal sub-capsular space is slow and metastases non-existent, 
while orthotopically injected cells grow and metastasize readily [44-49].  Bastide, et. al. 
[47] found that 80% of Nod/Scid had metastases 8 weeks after orthotopic implantation of 
human PC-3 cells.  Although very useful, orthotopic studies using human cell lines are 
limited due to the small number of human prostate cancer cell lines available, their 
unknown genetic background, as well as uncertainty regarding the effects of long term in-
vitro culture.   
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Orthotopic injection of mouse prostate cancer cells offers significant advantages 
as an alternative to xenotransplantation of human prostate cancer cell lines.  The main 
advantage of using mouse prostate tumor cells is the ability to engineer a specific 
constellation of molecular mutations which will enable a mechanistic study of the 
molecular pathogenesis of prostate cancer growth and metastasis.  In addition, the 
problems of variability among human cell lines and of using long term culture adapted 
cells is largely eliminated.  An additional potential benefit is the ability to use 
immunocompetent recipient mice, as modeling the interaction between cancer and the 
intact immune system is essential for an optimal cancer model.   
Recent advances in in-vivo bioluminescent imaging have enabled the real-time 
assessment of tumor size and location as well as the presence of metastases.  Orthotopic 
injection of bioluminescent human prostate cancer lines has been demonstrated to be a 
very efficient method to assay response of tumor and/or metastases to chemotherapy [50].  
The development of a transplantable bioluminescent mouse orthotopic prostate cancer 
model is an important step in providing flexibility in a model with well-defined genetic 
parameters for investigating the molecular mechanisms of prostate cancer growth and 
metastasis. 
 Orthotopic injection also solves many of the problems with GEMs that often 
render them unsuitable for preclinical research.  In mouse models of prostate cancer, the 
prostate specific promoters often result in multifocal expression of transgenes or Cre-lox 
targeted deletions of tumor suppressor genes.  This often leads to diffuse transformation 
of the prostate epithelium and eventual obstruction of urinary outflow as the tumors 
invade and compress the urinary bladder, ureters, and urethra.  Thus morbidity in the 
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mice is due to the secondary effects of the primary tumor, and not due to metastatic 
CRPC as is most common in humans.   Some of the other problems associated with 
mouse prostate cancer models include not being able to reliably reproduce bone 
metastases, one of the most important metastatic sites in human prostate cancer, and 





 model whose development and characterization is 
described within this dissertation project, [40] as well as the Nkx3.1; Pten
-/-
[11] model 
have demonstrated progression to CRPC, however the model itself does not metastasize.  
Numerous mouse models of prostate cancer have been developed using a wide range of 
prostate specific promoters to drive increased expression or deletion of oncogenes or 
tumor suppressor genes [32, 51].  While many of these mouse models recapitulate most 
of the range of prostate cancer phenotypes observed in humans, they fail to reproduce one 
of the most important features associated with morbidity/mortality in humans: bone 
metastases.   Some of the most relevant models incorporate common molecular lesions 
that are observed in humans including: TMPRSS2-ERG translocations [52], Pten/Tp53 
loss [40], Pten/Smad4 [39] loss, and combining loss of the Nkx3.1 homeobox gene with 
Pten loss which results in upregulation of both RAS-MAPK and PI3K-AKT signaling 
[11, 53]. 
III. Prostate cancer metabolism 
A. General features of cancer metabolism 
One consistent feature of the metabolic changes associated with carcinogenesis is 
an increase in aerobic glucose metabolism, named The “Warburg effect” after its 
discovery by Warburg [54].  Aerobic glycolysis is very inefficient at producing ATP with 
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only 2 molecules of ATP produced per molecule of glucose vs. 36 molecules of ATP 
produced with complete oxidation via oxidative phosphorylation [55].  However aerobic 
glycolysis provides carbon substrates for the upregulated anabolic processes required for 
rapidly growing tumor cells such as nucleic acid production via the pentose phosphate 
pathway, lipogenesis, and protein synthesis [56, 57].   In addition, the lactate that is 
formed can be converted back into pyruvate for the TCA cycle or provide carbons for 
amino acid synthesis, or can be made into Acetyl-CoA for use in de-novo lipogenesis 
[58]. The mechanism of the increased glycolysis associated with the Warburg effect has 
been demonstrated to be largely due to mitochondrial bound HK II, the first and rate 
limiting enzyme in glycolysis which allows escape from product inhibition (G-6-P) as 
well as the preferential access to mitochondrial ATP [59-61].  
Some of the cell signaling mechanisms that have been shown to increase tumor 
glycolysis include: activation of PI-3 Kinase or disruption/deletion of Pten with 
activation of AKT [62-67]  The mechanisms of increased glycolysis due to AKT 
activation include: increased expression of surface membrane glucose transporters, 
increased mitochondrial binding by HK II, and activation of phosphofructokinase one of 
the key regulators of glycolytic rate [62]. As a large percentage of advanced prostate 
cancers display AKT activation [11], increased glycolysis and mitochondrial associated 
HK II would be expected.  However, little research has been done on the activity and 
cellular distribution of HK II in prostate cancer.   
B. General features of prostate metabolism 
The energy metabolism of normal prostate epithelial cells differs from virtually 
all other epithelial cells in that large amounts of citrate are secreted into the prostatic 
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fluid, instead of being completely oxidized in the TCA cycle and used for oxidative 
phosphorylation.  The result is a large amount of “wasted” energy as large numbers of 
ATP molecules that could have potentially been produced through complete oxidation of 
citrate are “lost” to the citrate in prostatic secretions.  The mechanism of this truncated 
TCA cycle is due to zinc accumulation in the mitochondria of prostate cells, which 
inhibits the mitochondrial aconitase enzyme responsible for converting citrate into iso-
citrate in the TCA cycle [68]. 
C. Prostate cancer metabolism: androgen dependence 
Androgens regulate the unique energy metabolism of normal prostate epithelium 
and primary prostatic adenocarcinomas which is based on lipid metabolism rather than 
the more common emphasis on glycolysis in most other tumor types.  The lipid anabolic 
and catabolic processes in normal and transformed prostate epithelial cells are largely 
dependent upon the activity of the sterol regulatory element binding protein (SREBP).  
The SREBP is responsible for regulating the transcription of several genes involved in 
lipid metabolism. This is in part responsible for a reliance on lipid metabolism in primary 
androgen dependent prostate adenocarcinomas, including lipid uptake, lipogenesis, and 
utilization of lipids for energy production [16, 69, 70] 
Primary prostate cancer, unlike most other tumors, does not rely on aerobic 
glycolysis but rather mitochondrial fatty acid B-oxidation (CPT1) as the dominant 
bioenergetic pathway [71].  Lipid metabolism in prostate cancer cells, especially 
lipogenesis, is androgen dependent, in part due to the indirect activation of the SREBP 
pathway by androgen receptor signaling [16, 70].  Lipid uptake is also androgen 
regulated as membrane lipid transporters (FABPpm) have been demonstrated to be 
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upregulated in response to androgen stimulation [69].  mTOR signaling also activates the 
SREBP [72, 73] and plays a role in regulating prostate cancer lipid metabolism [74].  
Positron Emission Tomography (PET) studies indicate poor glucose uptake (F18-FDG) 
with increased lipid uptake/utilization (C11-acetate uptake) in clinical studies on primary 
prostate adenocarcinomas [75, 76].  The important role of androgens in regulating the 
energy metabolism of normal and primary prostate cancer led us to study the effects of 
androgen withdrawal on prostate cancer metabolism.  We hypothesize that androgen 
depletion will result in a strong selection pressure to adapt to a carbohydrate based rather 
than a lipid based energy metabolism. 
D. Prostate cancer metabolism in castrate resistant disease 
Evidence from in-vivo and in-vitro studies in both humans and mouse models 
support a switch to an increased reliance on glycolysis instead of fatty-acid B-oxidation 
for energy metabolism in CRPC [16]. Of particular relevance to this dissertation research 
is the fact that androgen independent xenografts and cell lines increased F18-FDG uptake 
as well as increased expression of the GLUT1 glucose membrane transporters, as 
compared to androgen dependent cell lines and xenografts [77, 78]. The data suggesting 
increased reliance upon glycolysis as compared to fatty acid B-oxidation following 
androgen deprivation led us to hypothesize that for CRPC in our mouse model, increased 
glycolysis would be an adaptive mechanism in the androgen deprived environment.  In 
addition to the energetic benefit, the increased carbon precursors from  glycolysis can 
fuel anabolic processes such as shunting glucose-6-phosphate into the pentose phosphate 
pathway, and citrate into the cytoplasm for de novo lipogenesis.  However, the results 
from studies on the effects of androgens on prostate cancer metabolism are often difficult 
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to interpret and give confounding results, likely due to the high degree of heterogeneity in 
prostate cancer.  In fact, it has been shown that gene expression analysis of metabolic 
genes in the same cell lines from different labs have produced significantly different gene 
expression signatures [15].  This highlights the necessity of using metabolism gene 
expression and metabolite screening data as a guide for more refined assays designed to 
validate the general metabolic trends suggested by the broad spectrum metabolic screens.  
We propose that the most relevant way to model the changes in energy metabolism 
associated with castrate resistant prostate cancer (CRPC) is to use a genetically defined 
mouse model (containing common genetic lesions present in human CRPC).  Here one 
can perform metabolic assays on the primary androgen dependent tumors and compare 
the results to those from androgen independent tumors that have been allowed to re-grow 
after initial androgen deprivation and evolution into CRPC through the selection process 
present in the androgen deprived environment. 
E. Increased glycolysis in castrate resistant prostate cancer: the role of 
hexokinase II in energy production 
The increased glycolysis associated with aerobic glycolysis in tumors (the 
Warburg effect) has been shown to be largely due to an increase in cytoplasmic and even 
more importantly mitochondrial associated HK II [59].  
HK II catalyzes the irreversible first step in glycolysis: 
Glucose + Mg-ATP        Glucose-6-phosphate + Mg-ADP [61].  Once phosphorylated, 
glucose is now trapped inside the cell and can be used for energy production via the 
glycolysis-TCA cycle-oxidative phosphorylation pathways.  Alternatively glucose-6-
phosphate can be shunted to the pentose-phosphate-pathway (PPP) for nucleic acid 
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production.  Glucose-6-phosphate can be shunted out of the energetic pathways for other 
anabolic processes such as de-novo lipogenesis by the shunting of citrate out of the TCA 
cycle and into the cytoplasm.  In mammals there are 4 hexokinase isoforms (1-4), with 
HK-1 and HK-2 being able to attach to the outer mitochondrial membrane, HK-3 is 
located in the perinuclear compartment, and HK-4 is located in the cytosol in certain 
organs such as the liver and pancreas [61].  HK-2 is the predominant isoform expressed 
by malignant tumors and in tumors is often located on the outer mitochondrial membrane 
voltage dependent anion channel (VDAC) [58, 79].  Several metabolic and cell-signaling 
pathways have been implicated in regulating HK II-mitochondrial VDAC binding 
including: intracellular lactate, pH, ATP/ADP ratio, glucose/glucose-6-phosphate ratio, 
AKT, and AMPK signaling [80-82].  Blocking PI3K-AKT signaling has been shown to 
inhibit the  HK II-mitochondrial association in human hepatocellular carcinoma cell lines, 
as has PI3K independent activation of pAKT via AMPK signaling [83].  Insulin 
signalinghas also been shown to participate in the binding of HK II to the VDAC [58].  In 
tumor cells glycolysis and oxidative phosphorylation can by spatially coupled through the 
binding of HK  II to the VDAC on the outer mitochondrial membrane (OMM). This 
provides a dramatic energetic benefit by allowing HK II direct access to high 
concentrations of mitochondrial ATP through the OMM adenine nucleotide translocase 
exchange channel and VDAC [84], rather than relying on the lower concentration of ATP 
in the cytoplasm.  In normal tissues that do not express significant levels of HK II such as 
the liver and pancreas, which express primarily the lower glucose affinity hexokinase IV 
isoform, one of the earliest metabolic adaptations associated with carcinogenesis is a 
switch from the hexokinase IV isoform to the expression of the higher glucose affinity 
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HK II isoform [60, 85-88].  Thus in human hepatocellular carcinoma cells, HK II is 
switched on while hexokinase IV is silenced [83].  In addition to the obvious energetic 
benefit to increasing glucose-6-phosphate production, this increased activity of HK II 
also provides increased carbon substrates to fuel nucleic acid production in the pentose 
phosphate pathway and for de-novo lipogenesis via the shuttling of citrate into the 
cytoplasm at the expense of fueling the TCA cycle.  In addition, remaining bound to the 
outer mitochondrial membrane allows HK II to escape inhibition from its product 
glucose-6-phosphate [61]. 
F. Increased glycolysis in castrate resistant prostate cancer: the role of 
hexokinase II in pro-survival mechanisms 
Perhaps just as important as the increased energy metabolism, and production of 
carbon substrates for anabolic processes required for rapidly growing tumor cells, is the 
fact that the binding of HK II to the VDAC directly inhibits the binding of several pro-
apoptotic proteins (ie: Bax, Bak, Bad), and inhibits their oligomerization and initiation of 
apoptosis [89, 90].  Releasing the VDAC bound HK II via various inhibitors [91-93] 
strongly induces apoptosis in these previously resistant tumor cells.  The attachment of 
HK II to the outer mitochondrial VDAC has been shown to be an adaptation to inhibition 
of glycolysis with 2-deoxyglucose, which is used to simulate low glucose conditions and 
metabolic stress in-vitro [94].  Increased HK II was shown by Ahn, et. al [83] to lead to 
increased survival in human hepatocellular carcinoma cells when exposed to the 
chemotherapeutic agent cisplatin.  
This anti-apoptotic role of mitochondrial-associated HK II has been recognized as 
a potential drug target.   Disrupting the HK II-mitochondrial interaction with compounds 
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such as 3-bromopyruvic acid, clotrimazole, bifanazole, methyl jasmonate, or a 
competitive peptide inhibitor has already demonstrated to be highly efficacious against 
tumors in animal models [95-98]. Targeting prostate cancer glycolysis with the inhibitory 
2-Deoxyglucose has also been attempted in human clinical trials [99].  
Inhibition of PI3K-AKT signaling dissociated mitochondrial bound HK II and led to 
increased apoptosis in human hepatocellular carcinoma cell lines [83].  The use of a HK 
II inhibitor has also been shown to have a synergistic effect in combination with a 
standard chemotherapeutic, cisplatin, in human colon cancer cells in vitro [100] 
Despite the importance of HK II expression and cellular distribution in tumor metabolism 
and survival, no one has yet investigated the role of HK II in promoting prostate 
carcinogenesis or in the evolution of androgen independent growth.  As we hypothesize 
that the evolution of CRPC will be associated with a switch to a more glycolytic 
phenotype in prostate cancer, it is logical to hypothesize that an increased glycolysis will 
be associated with increased total and mitochondrial-associated HK II. 
G. The role of AKT signaling in regulating hexokinase II 
As our mouse model demonstrates increased AKT activation due to the loss of the 
inhibitory effects of Pten, it is important to consider the role of PI3K/AKT signaling in 
HK II levels and cellular localization. Mitochondrial HK II is a major effector of AKT 
mediated tumor cell growth and survival [58, 90, 101].  Although the exact mechanism 
by which activated AKT increases mitochondrial-bound HK II is not currently known, 
circumstantial evidence points to AKT playing a role in maintaining the mitochondrial-
HK II association and inhibiting the release of cytochrome c and blocking apoptosis [90].  
This is based on the findings that AKT is necessary for maintaining mitochondrial 
 17 
 
integrity and preventing cytochrome c release following apoptotic triggers.  However, 
glucose is required for AKT signaling to prevent apoptosis.  Cells in which AKT genes 
have been deleted lose the ability to maintain HK II bound to the outer mitochondrial 
membrane at the VDAC [102].  Similarly cells treated with a PI3-K inhibitor also had a 
reduced ability to maintain the mitochondrial-HK II association.  Using drugs to 
dissociate HK II from the mitochondrial VDAC also ablated the anti-apoptotic effects of 
activated AKT.  Even in the absence of the pro-apoptotic factors Bax and Bak, Majewski 
et. al, [102], showed that forced dissociation of HK II from the VDAC caused 
cytochrome c release into the cytoplasm and apoptosis.  The role of activated AKT in 
regulating glycolysis via HK II levels and mitochondrial association is another piece of 




 mouse model will be 
associated with increased total and mitochondrial associated HK II.  
 
IV. Thesis Goals and Outline 
A. There are two major aims of this dissertation research: 
1) Develop and characterize a mouse model of Pten/Tp53 deleted prostate cancer to 
investigate: the innate presence of castrate resistant prostate cancer (CRPC), the 
identity of tumor and metastasis initiating cells, and the lineage specific 
development of epithelial-to-mesenchymal transition.    
Hypothesis: Orthotopically injected Pten and Tp53 mouse prostate carcinoma 
will be capable of androgen independent (castrate resistant) growth and 
metastasis.  The phenotypic heterogeneity: adenocarcinoma, adenosquamous 
carcinoma, basal/squamous carcinoma, and sarcomatoid carcinoma, each with 
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occasional neuroendocrine differentiation, that are observed in primary tumors 
and metastases are due to a multi-potent tumor and metastasis initiating prostate 
progenitor cell that is capable of differentiating along basal and luminal lineages 
with occasional neuroendocrine differentiation.  
2) Determine if there are metabolic differences between androgen dependent and 
castrate resistant prostate cancer that may serve as adaptations for the evolution 
and survival of CRPC.   
Hypothesis: CRPC will be associated with increased glycolysis as an adaptation 
to survival in androgen independent conditions in contrast to the reliance on lipid 
metabolism in androgen replete conditions.  This increased glycolysis is adaptive 
not only to compensate for energetic needs, but also to provide carbon precursors 
for anabolic processes such as lipogenesis and nucleic acid synthesis via the 
Pentose phosphate pathway, as well as to prevent metabolic stress induced 
apoptosis. 
 
B. Dissertation outline  
The 2 chapters of this dissertation will be presented in the form of two separate 
manuscripts for publication: 
 Chapter 1 describes the generation and characterization of the model.  The initial 
thorough histopathological examination showed significant histopathological 
heterogeneity.  This led us to investigate heterogeneity in lineage differentiation 
and phenotypic plasticity in tumor and metastasis initiating cells, as well as 
epithelial-to-mesenchymal transition (EMT).  This manuscript has been published 
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in the American Journal of Pathology: Prostate epithelial Pten/TP53 loss leads to 
transformation of multipotential progenitors and epithelial to mesenchymal 
transition [40]. 
We performed our investigations on two well characterized clonal cells lines.  The 
first, referred to as Clone 1, was a bipotential stem/progenitor cell line capable of 
differentiating along both luminal and/or basal lineages, with occasional neuroendocrine 
marker expression.  The second, referred to as Clone 2, was a luminal progenitor cell line 
that produced adenocarcinoma with occasional neuroendocrine marker expression, with 
increasing EMT through progression to sarcomatoid carcinoma.  Both of these clonal cell 
lines were capable of producing adenocarcinoma with a similar phenotype to that seen in 
most human prostate adenocarcinomas: CK8/CK18 luminal cells with occasional 
expression of neuroendocrine markers (ie: synaptophysin),  The results of this 
investigation indicate that Pten/TP53 loss in the mouse prostate epithelium leads to the 
expansion of multipotent tumor and metastasis initiating cells that are capable of 
differentiating along luminal and/or basal lineages, with occasional neuroendocrine 
differentiation.   
Androgen deprivation led to the development of castrate resistant prostate cancer, and 
metastasis initiating cells that were primarily bi-potential progenitors expressing both 
basal and luminal markers, in contrast to androgen replete tumors where metastasis 
initiating cells were primarily of the luminal lineage.  Epithelial-to-mesenchymal 
transition (EMT) was confirmed in cells of the luminal lineage derived from Clone 2 
orthotopic tumors.  These results highlight the role that TP53 loss plays in regulating the 
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differentiation status of tumor and metastasis initiating cells, as well as its role in 
promoting EMT.  
 Chapter 2 describes the investigation into the metabolic differences between 
androgen replete and androgen deprived orthotopic Pten/TP53 mouse prostate 
carcinomas that were derived from Clone 1, the unique stem/progenitor cell line 
capable of multi-lineage differentiation.  An initial metabolomic screen provided 
the rational for this chapter’s investigation as the preliminary results indicated an 
increased carbohydrate utilization in the androgen deprived tumors.   
The results of this investigation indicate that increased glycolysis is associated with 
stem/progenitor cell mediated CRPC.  This increased glycolysis is the result of increased 
cytoplasmic and mitochondrial HK II.  Increased total and mitochondrial-associated HK 
II provides a novel metabolic adaptation for the evolution of CRPC due to increased 
energy production, increased production of anabolic precursors, and protection from 
apoptosis.  This metabolic adaptation provides a new target in the fight against this 















Chapter 2: Prostate Epithelial Pten/TP53 Loss Leads to Transformation of 
Multipotential Progenitors and Epithelial to Mesenchymal Transition 
 
I. Abstract 
Loss of PTEN and loss of TP53 are common genetic aberrations occurring in prostate 
cancer.  PTEN and TP53 contribute to the regulation of self-renewal and differentiation in 
prostate progenitors, presumptive tumor initiating cells for prostate cancer. Here we 
characterize the transformed phenotypes resulting from deletion of the Pten and TP53 






 model of 
prostate cancer, we describe the histologic and metastatic properties of primary tumors, 
transplanted primary tumor cells, and of clonal cell lines established from tumors.  
Adenocarcinoma was the major primary tumor type that developed, which progressed to 
lethal sarcomatoid carcinoma around 6 months of age. In addition, basal carcinomas and 
prostatic urothelial carcinoma were observed.  We show that tumor heterogeneity 
resulted, at least in part, from the transformation of progenitors with biphenotypic 
potential.   CK8+ luminal epithelial cells were capable of undergoing epithelial to 
mesenchymal transition in vivo to sarcomatoid carcinomas containing osseous 
metaplasia.  Metastasis rarely was observed from primary tumors, but metastasis to lung 
and lymph nodes occurred frequently from orthotopic tumors initiated from a 
biphenotypic clonal cell line.  Androgen deprivation influenced the differentiated 
phenotypes of metastases.  These data show that one functional consequence of 




Prostate cancers display a range of clinical behavior, from slow-growing tumors of 
minor clinical significance to locally aggressive and ultimately metastatic disease.  
Human prostate adenocarcinoma has a mature luminal phenotype characterized by 
cytokeratin 8 (CK8) and androgen receptor (AR) expression and PSA production.  
Progressive prostate cancer (PC) is almost always treated with androgen deprivation 
therapy (ADT), but despite such treatment, approximately 10% of prostate cancers 
progress to metastatic disease [103].  Defining mechanisms of resistance to androgen 
deprivation and progression to metastasis would be significantly aided by the availability 
of genetically-defined models of prostate cancer progression.  
One of the most common genetic alterations in prostate cancer is deletion of at least 
one copy of the PTEN tumor suppressor, which occurs in approximately 70% of human 
prostate cancers.  Biallelic deletion of PTEN and the associated increase in AKT 
phosphorylation, which occurs in roughly 25% of PC, is correlated with resistance to 
ADT [104]. A recent genomic profiling study of mostly primary prostate cancers 
demonstrated that 21% of cases had either a hetero- or homozygous copy number loss of 
TP53 [105].  Other large scale studies using combined immunohistochemistry and 
sequencing approaches have shown that TP53 mutations occur in approximately 5% of 
primary tumors and at much higher frequencies in lymph node metastases (16%) and 
castrate-resistant (26%) tumors [106, 107].  Additionally, TP53 mutations were found to 
be independent predictors of tumor recurrence in low and intermediate grade cancers.   




Clinical and experimental evidence indicates that a major determinant of metastatic 
potential is the differentiated phenotype of the cancer cell of origin [108].  Multipotential 
progenitors as well as luminal progenitors are proposed cells of origin for prostate cancer 
[109].  Prostate cancer metastases are found most commonly in the bone, lymph nodes, 
liver, lungs, and dura mater [103, 110, 111].  Within bone metastatic sites there is a 
remarkable degree of phenotypic heterogeneity among tumor cells when comparing 
different patients as well as multiple sites within individual patients [103, 111].  This 
heterogeneity includes differences in morphology as well as immunophenotypes for 
differentiation markers.  Most commonly, prostate cancer metastases tend to have a 
poorly differentiated morphology and not infrequently are composed of admixtures of 
mature luminal and neuroendocrine cells and occasionally contain biphenotypic 
intermediate cells expressing both basal and luminal cytokeratin markers [103, 112].  
Thus, prostate cancer metastases develop from initiating cells with multi-lineage potential 
and/or from cells with significant phenotypic plasticity.  
Modeling prostate cancer in mice generally involves the use of cell-type specific 
promoters to achieve over-expression of oncogenes or deletion of tumor-suppressors, 
mimicking commonly observed genetic aberrations in human prostate cancer.  Deletion 




initiated by pan prostate epithelial cell expression of      
PB-Cre4 leads to the expansion of basal cells and the development of invasive 
adenocarcinoma with an intermediate/luminal phenotype [113].  On the other hand, 
deletion of Pten driven by PSA or NKX3.1 promoters in luminal progenitors also leads to 
PIN/adenocarcinoma [114, 115].  These data suggest that more than one differentiated 
cell type can serve as a target cell population for Pten deletion-mediated oncogenesis.   
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Previous investigations into the effect of combined genetic deficiencies in mouse 
models of prostate cancer have demonstrated that prostate epithelial cell-specific loss of 
Pten and TP53 resulted in significantly more penetrant and rapidly developing PC than 
Pten deletion alone, while loss of TP53 only did not lead to any notable phenotype [35].  
It was proposed that the synergistic effect of Pten/TP53 deletion results from a loss of 
TP53 dependent cellular senescence secondary to Pten loss because Pten/TP53 null 
PIN/adenocarcinoma tumors demonstrated many fewer senescent tumor cells than Pten 
null tumors [35]. Also significant, we have shown using in vitro analyses that Pten and 
TP53 play a role in regulating self-renewal and differentiation of prostate stem/progenitor 
cells [116].  Therefore, we hypothesized that increased prostate progenitor amplification 
and deregulated differentiation contribute to the more aggressive and lethal phenotype of 
tumors initiated following Pten/TP53 loss as compared to Pten loss only.   
Increased numbers and/or plasticity of undifferentiated prostate epithelial cells might 
be expected to give rise to multiple tumor histologies.  A longitudinal description of 








mouse model demonstrated a 
remarkable degree of cell lineage heterogeneity in primary tumors.  We hypothesized that 
the epithelial heterogeneity derived from the transformation of a multi-potential 
progenitor cell.  In addition, the occurrence of CK8+/Vimentin+ cells in tumors 
undergoing epithelial to mesenchymal transition (EMT), suggested an epithelial origin 
for the large spindle cell tumors that often caused morbidity/mortality in these mice.  In 
order to investigate the origin and characteristics of primary tumor heterogeneity, clonal 
epithelial cell lines were established from tumors to evaluate the differentiation potential 
of clonally-derived tumor initiating cells. Upon in vivo inoculation, individual cell lines 
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recapitulated specific features of heterogeneous primary tumors, including EMT and 
biphenotypic basal and luminal epithelial differentiation.  The biphenotypic line 
described here was androgen-sensitive and highly metastatic, characteristics that allow 
modeling of prostate cancer progression. 
 
III. Results 
A. PB-Cre4+; Ptenfl/fl;TP53fl/fl mice develop adenocarcinoma with 
progression to sarcomatoid carcinomas but not metastasis. 








 mice demonstrated significantly 






  mice (Fig. 1A).  A 









developed severe mouse prostatic intra-epithelial neoplasia (mPIN) as early as 8 weeks 
with progression to adenocarcinoma by 12 weeks.  All mice eventually succumbed by 30 
weeks as the result of urinary tract obstruction by sarcomatoid carcinomas (Fig. 1).  
Mouse prostatic intraepithelial neoplasia (mPIN) lesions were comprised of large 
numbers of cytokeratin 8 (CK8) +/cytokeratin 5 (CK5) +/TP63- intermediate cells and 
CK8+/CK5-/TP63- luminal cells (Fig. 2C), with occasional foci containing small 
increases in CK8-/CK5+/TP63+ basal cells.  CK8+/CK5- cells increased in proportion to 
CK8+/CK5+ cells in invasive adenocarcinoma relative to PIN (Table 1 and Fig. 2D), 
suggesting increased accumulation of differentiated luminal cells in adenocarcinoma.  
Co-expression of the neuroendocrine marker synaptophysin and CK8 were occasionally 
observed in focal regions of adenocarcinoma and mPIN (see Supplemental Figure S1A).  
At approximately 15-19 weeks, sarcomatoid carcinomas could be observed arising in the 
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wall of the anterior prostate, adjacent to poorly differentiated adenocarcinoma (Fig. 2G).  
As adenocarcinoma progressed to sarcomatoid carcinoma, there was a reduction/loss of 
E-cadherin and CK8 coupled with an increase in vimentin expression (Table 1).  
Occasional neoplastic spindle-shaped cells co-expressing CK8 and vimentin were 
observed, indicating epithelial to mesenchymal transition (see Supplemental Figure S2).  
Nuclear expression of the EMT marker, slug, was detected by IHC in sarcomatoid 
carcinomas (see Supplemental Figure S2), but was rarely detected in adenocarcinoma.  
Nuclear androgen receptor expression as determined by IHC decreased with disease 
progression. In mPIN, there was strong nuclear expression of AR in luminal cells.   In 
adenocarcinoma, there was more heterogeneity relative to mPIN in the levels of AR 
expression, with loss of AR in occasional cells. AR was often very low or undetectable in 
spindle cell carcinoma (Table 1). At the time of death or euthanasia, distant metastases 
were not observed; however lymphovascular and perineural invasion was common (Fig. 
2B&E), and small aggregates of tumor cells occasionally were detected in sublumbar 
































 littermates (n=38) 
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 mice in each age group 
with a tumor containing the indicated phenotype (%incidence): 10-14 weeks (n=14), 15-
19 weeks (n=17), 20-25 weeks (n=10), 26-30 weeks (n=12) : mouse prostatic 
intraepithelial neoplasia (PIN), Adenocarcinoma (Adeno), Basal/squamous carcinoma 























 primary tumors or tumors arising from orthotopically transplanted 
tumor cell suspensions.  
 
 
Mouse prostatic intraepithelial neoplasia (mPIN), adenocarcinoma (Adeno.), sarcomatoid 
carcinoma (Sarcomatoid), and basal/squamous carcinoma (Basal/Squamous).  +++ 
marker present in most or all cells (80%-100%), ++ marker present in many cells, 
however there are significant numbers of cells that lack expression (50%-80%), + marker 
present in a minority of cells (5%-50%), +/- marker is present in only rare populations of 
cells (less than or equal to 5%), - absence of marker.   ↑Denotes increased and ↓denotes 
decreased IHC labeling intensity relative to epithelial cells in wild-type control prostate.  
Synapto.=synaptophysin.  (*) In mPIN there are areas with minimal proliferation of 
TP63+ cells along the basal lamina, and rarely in the cell layer superficial to the basal cell 
layer, as well as areas lacking TP63+ cells.  (†) In poorly differentiated adenocarcinoma 
there is often a decrease in intensity of  E-cadherin labeling as well as the presence of 
rare vimentin + cells.  



















































































































































 mice display a diversity of tumor phenotypes. 
Panels A-F are different regions of tumor from a single mouse.  A) High grade mouse 
prostatic intraepithelial neoplasia (mPIN), 14 week old mouse dorsal prostate.  In an 
mPIN gland, the lumen (L) is almost completely occluded by a marked proliferation of 
neoplastic epithelium.  The neoplasm does not invade the basement membrane and is 
bounded entirely by smooth muscle (arrow), H&E.  B) Adenocarcinoma in periphery of 
the dorsal prostate.  Neoplastic glands invade the stroma (s) adjacent to a prostatic nerve 
ganglion (arrow), H&E.  C&D) Double immunofluorescence for CK8 (Green; Alexa 
Fluor 488) and CK5 (Red; Alexa Fluor 586) on mPIN (C) and adenocarcinoma (D).  In 
mPIN (C) there are often cells with co-expression of CK5 and CK8 (arrow).  In 
adenocarcinoma (D) there are cells with CK8/CK5 co-expression (short arrow), 
CK8+/CK5- cells (arrow head), and occasionally CK5+/CK8- cells (long arrow).  E)  
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Vascular invasion.  Tumor embolus (asterisk) within lumen of blood vessel is comprised 
of cells that label positive for CK8.  Arrows indicate endothelial cells lining luminal 
surface of blood vessel, anti-CK8 and hematoxylin.  F) Prostatic urothelial carcinoma in 
proximal prostatic ducts adjacent to the urethral muscularis (m). Note packets of prostatic 
urothelial carcinoma cells separated by a fine fibro vascular stroma, H&E.  G) 
Sarcomatoid carcinoma in 28 week old mouse.  Note streams of spindle shaped cells with 
large oval nuclei that lack glandular differentiation, H&E.   H) Basal/Squamous 
carcinoma in anterior prostate of 28 week old mouse.  Note palisading basal cells (arrow) 
on basement membrane with overlying stratified squamous epithelium (sq) and 
superficial keratin layer (k), H&E.  Scale bar for A, B, E-H:100m (Images taken at 











B. Primary tumors contain additional minor components of other tumor 
phenotypes. 







 tumors occasionally contained regions with a basal/squamous or 
urothelial phenotype (Fig. 2F&H).  Basal/squamous regions often featured keratin 
production (Fig. 2H) and were characterized by CK5 and TP63 expression (Table 1).  
Occasionally in the most proximal regions of the prostatic lobes where the prostatic ducts 
traverse the urethral muscularis and communicate with the urethra, there was carcinoma 
with a urothelial pattern, referred to as prostatic urothelial carcinoma (CK5+/TP63+ with 
rare CK8+ cells) (Fig. 2F).  However, no tumors of the urinary bladder or urethral 
transitional epithelium were observed in any mice.  Frequently, basal/squamous 
carcinoma, adenocarcinoma, and prostatic urothelial carcinoma were present in the same 
tumor.  All tumor types displayed heterogeneous expression of the neuroendocrine 
marker synaptophysin (see Supplemental Figure S1A).  Chromogranin A was only rarely 
observed in isolated individual cells, indicating a not fully differentiated neuroendocrine 
phenotype.  As anticipated, immunohistochemistry failed to detect TP53 or Pten 
expression in tumor cells of all histological types while Pten expression could be detected 












 tumor initiating 
cells does not lead to metastasis. 
The rapid growth of primary tumors in this model led to early mortality, which 







 tumor cells, we injected into the dorsal prostatic 
lobe of nude mice single cell suspensions of primary mouse prostate tumors obtained 






 mice.  A constitutively-expressed 
luciferase construct was introduced by cross-breeding into the tumor model to provide a 
noninvasive marker for monitoring the growth and potential metastasis of transplanted 
cells [117].  Tumors from transplant recipients were harvested upon morbidity, an 
average of 27 weeks post-injection. Orthotopically transplanted tumor cells primarily 
formed orthotopic PIN (oPIN) and adenocarcinoma, which expressed markers similar to 
equivalent primary neoplasms (Figs. 3&4, Table 1 and see Supplemental Figure S1B).  
Basal/squamous carcinomas and prostatic urothelial carcinomas developed infrequently.  
Notably, although there were occasional foci of EMT with individual or small clusters of 
tumor cells acquiring spindle cell morphology, there were no discrete sarcomatoid 
carcinomas.  There was widespread lymphovascular and perineural invasion in transplant 
recipients; however, metastases were not observed with either ex-vivo bioluminescent 
imaging of recipient mouse organs or by histopathological examination.  The lack of 
metastasis in orthotopically-transplanted mice, in which there was an additional 12-16 
weeks for orthotopic tumor development, supports the conclusion that pan-epithelial 
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 mouse primary prostate 
carcinoma cells favors the development of adenocarcinoma. Orthotopic prostate 
carcinoma histological pattern as a percent of total tumor area for each individual 
orthotopic tumor, n=12 (oPIN/Adeno: mouse orthotopic prostatic intraepithelial 
neoplasia/adenocarcinoma; Basal/Squam: basal/squamous carcinoma; Urothelial: 
urothelial carcinoma).  Nude mice were injected into one dorsal prostatic lobe with single 














Figure 4.  Orthotopic prostatic intraepithelial neoplasia (oPIN) and orthotopic 







tumor cells.  Sequential serial sections of recipient nude mouse wild type prostate (A-C), 
oPIN (D-F), and oAC (G-I), were stained with H&E (A,D,G), CK8 (B,E,H), and CK5 
(C,F,I).  A) Recipient nude mouse wild type dorsal prostate.  B) Luminal cells express 
cytokeratin 8 (CK8) while C) basal cells express cytokeratin 5 (CK5), (arrow heads). D) 
Orthotopic PIN with marked proliferation of neoplastic glandular epithelium in a 
cribiform pattern, E) most of the epithelial cells express CK8, F) There is a nearly 
complete basal cell layer comprised of CK5 expressing cells but no smooth muscle layer.  
 36 
 
G) Orthotopic adenocarcinoma, H) the neoplastic epithelium expresses CK8, I) with loss 
of the CK5+ basal cell layer.  All images taken at 400X, scale bar = 100m.   
D. Clonally derived cell lines produce tumors containing multiple 
lineages. 
The tumor heterogeneity in primary and orthotopic prostate carcinomas could be 
the result of transformation of multiple, distinct, lineage-committed tumor progenitor 
cells and/or of tumor progenitors with multi-lineage potential.  As one approach to begin 
addressing the differentiation potential of tumor-initiating cells, we derived several clonal 
cell lines from six separate orthotopic carcinomas.  Clonal cell lines were 
immunophenotyped at passages 4 or 5 for CK5, CK8, and vimentin.  The characteristics 
of 9 cell lines that were further expanded and tested for tumorigenicity are shown (Table 
2).  With the exception of clone 8 that was composed of CK8-/CK5+ cells, all the clones 
contained CK8+ cells and a variable percentage of double positive CK8+/CK5+ cells.  
Clonal cell lines appeared to produce continuously differentiating cells as individual 
colonies derived from single cells contained cells with heterogeneous marker expression.  
Cell suspensions were injected subcutaneously into nude mice.   The basal cell phenotype 
clone did not form tumors, while 7/8 of the CK8+ clones were tumorigenic.  Tumors with 
mixed histologies developed from 5/7 lines, and adenocarcinoma and sarcomatoid 
carcinoma developed from clones 6 and 7, respectively.  Three cell clones (clones 1, 3, 
and 4) demonstrated the capacity for biphenotypic basal and luminal differentiation, 
suggesting origins of the cell lines with bipotential progenitors.  In addition, the 
development of subcutaneous sarcomatoid carcinomas from three clonal epithelial cell 
lines (clones 2, 5, and 6) formally demonstrates the epithelial origin of spindle cell 
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tumors in this model (Table 2). Sarcomatoid carcinoma tumors frequently displayed 
osseous and cartilaginous metaplasia, implying mesenchymal differentiation to the 
osteoblast and chondrocyte lineages.  One clone that produced biphenotypic tumors 
(Clone 1) and one clone that produced sarcomatoid carcinomas (Clone 2) were analyzed 
more extensively for the expression of lineage markers and for orthotopic tumorigenic 




















Table 2.   Summary of in-vitro and in-vivo phenotypes for Pten/TP53 null 
prostatic carcinoma clonal cell lines. 
 
Average percent of cells expressing CK5, CK8, and vimentin determined by 
counting at least 200 cells per clonal cell line.  ND; no cells detected expressing 
the marker in the entire well of an 8 well chamber slide containing approximately 
1800 cells.  <1%; less than 10 cells expressing the marker in the entire well of 
the chamber slide containing approximately 1800 cells.  Undiff.=undifferentiated 
carcinoma, adeno.=adenocarcinoma. 
  
E. Analysis of sarcomatoid carcinoma-producing Clone 2 
Clone 2 was comprised of primarily CK8+/CK5- cells with low numbers of 
CK8+/CK5+ cells.  As shown in Fig. 5, the Clone 2 cell line was characterized for RNA 
expression of a variety of markers including epithelial lineage: Krt5 (CK5), Krt8 (CK8), 
Krt18 (CK18), Krt14 (CK14), TP63, and Cdh1 (E-cadherin); mesenchymal lineage: Vim 
(vimentin), Cdh2 (N-cadherin), Acta2 (smooth muscle actin); progenitor: Itga6 
(integrin), Sox2, and Notch1; and prostate growth/differentiation: Myc, Sox9 genes.  
 In-Vitro                 In-Vivo 
Clone CK5 CK8 Vimentin Tumor# Subcutaneous Tumor Phenotype 
1 75% 100% ND 101 Basal/squamous>adenocarcinoma 
2 5% 100% ND 301 Sarcomatoid/undiff./adeno.>basal/squamous 
3 25-50% 100% <1% 211 Basal/squamous>adenocarcinoma 
4 90% 100% ND 211 Basal/squamous>adenocarcinoma 
5 75% 100% <1% 211 Sarcomatoid>basal/squamous>adeno 
6 75% 100% <1% 222 Sarcomatoid 
7 50-75% 75% <1% 222 Adenocarcinoma 
8 100% 0% ND 222 No Tumor Growth 
9 50-75% 100% ND 222 No Tumor Growth 
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An immortalized basal phenotype (CK5+/TP63+) cell line derived from wild-type 
prostate is shown for comparison.  Clone 2 showed a predominantly luminal epithelial 
expression pattern without evidence of Vim or Acta2 expression.  Interestingly, Clone 2 
expressed both Cdh1and Cdh2 as well as relatively elevated levels of Myc RNA (Fig 5A).  
As anticipated, Clone 2 cells demonstrated phospho-AKT and AR protein expression 
(Fig. 5B). 
Clone 2 cells gave rise to orthotopic tumors that were primarily sarcomatoid 
carcinomas with occasional foci of adenocarcinoma (Fig. 6 and see Supplemental Figure 
S3C-D). Orthotopic carcinomas generally displayed diffuse low to moderate levels of 
cytoplasmic synaptophysin expression. Three Clone 2 orthotopic tumors harvested at 6 
weeks were comprised of primarily adenocarcinoma containing a minority component of 
undifferentiated/early sarcomatoid carcinoma, while tumors harvested between 9 and 12 
weeks were comprised of a majority of sarcomatoid carcinomas with occasional small 
foci of poorly differentiated adenocarcinoma, demonstrating increasing EMT with time 
and expansion of orthotopic tumors. Tumors cells that co-expressed CK8 and vimentin 
were readily observed (see Supplemental Figure S3C). Osseous and cartilaginous 
metaplasia were common in Clone 2 orthotopic tumors (Table 3, see Supplemental 
Figure S3D).  Clone 2 rarely metastasized (Table 3); however, lymphovascular invasion 
was common and tumor emboli were occasionally observed in pulmonary capillaries, 
similar to the phenotype observed in late stages of the primary mouse model (see 





Figure 5. Expression of differentiation and signaling markers in cultured wild type 
prostatic basal cells (see Materials and Methods) and in Pten/TP53 deleted Clones 1 and 
2 prostatic carcinoma cell lines.  A) Quantitative RT-PCR analysis of mRNA levels for 
various markers. B) Immunoblot analysis for selected markers. pAKT=AKT 





Martin, et. al, Fig6 
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 carcinomas demonstrate multi-
lineage differentiation, metastasis, and epithelial to mesenchymal transition.  Sequential 
serial sections of a representative Clone 1 orthotopic prostate carcinoma (left column), a 
Clone 1 lung metastasis  originating from this same primary carcinoma (middle column), 
and a Clone 2 sarcomatoid carcinoma (right column), staining with hematoxylin and 
eosin (H&E), and immunohistochemistry for cytokeratin 8 (CK8), cytokeratin 5 (CK5), 
TP63, synaptophysin (SYN), and androgen receptor (AR).   Clone 1 gives rise to 
adenosquamous carcinomas  D) with  heterogeneous luminal cytokeratin 8 (CK8) 
expression, and G) basal cytokeratin 5 (CK5) expression. J) Definitive basal cells express 
nuclear TP63 (arrows).  M) Heterogeneous synaptophysin (SYN) expression is observed 
in both adenocarcinoma and squamous portions of Clone 1 orthotopic tumors.   P) 
Androgen receptor expression is heterogeneous ranging from strong nuclear expression 
(arrow) to weak nuclear and cytoplasmic expression (arrow head).   B) Clone 1 
orthotopic tumors commonly metastasize to the lungs where metastases display either a 
luminal phenotype or are biphenotypic. E) Shown is a luminal phenotype lung metastasis 
that co-expresses CK8, and H) CK5, but K) not TP63.  N) Synaptophysin expression is 
common in Clone 1 lung metastases.  Q) Androgen receptor expression in lung 
metastasis is generally low in the nucleus, yet high in the cytoplasm.  C) Clone 2 
orthotopic carcinomas undergo EMT to form sarcomatoid carcinomas with only 
occasional glandular differentiation.  F) Sarcomatoid carcinomas lose cytokeratin 
expression leaving only occasional foci with weak CK8 expression (arrows).  I) No CK5 
or L) TP63 expression is observed .  O) Weak cytoplasmic synaptophysin expression is 
common in clone 2 tumors.  R) Androgen receptor expression is heterogeneous and 
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generally lower in Clone 2, with most tumor cells having weak or absent nuclear 
expression, and low cytoplasmic expression.  All images taken at similar resolution 





Table 3.   Comparison of the prostatic carcinoma phenotypes derived from orthotopically 




Ten mice orthotopically injected with Clone 1 cells were selected for imunophenotyping 
of lung metastases.  Lung metastases were scored as a Luminal phenotype: all cells in the 
metastasis contain CK8 and/or CK5 and are negative for TP63, or Biphenotypic: all cells 
in the metastasis contain CK8 and/or CK5 and at least one cell is positive for TP63.  >; in 
Clone 2 orthotopic tumors sarcomatoid carcinoma was the dominant histological pattern.  
+ Androgen; subcutaneous androgen pellet was replenished at week 7 post orthotopic 
injection, - Androgen; subcutaneous androgen pellet was removed at week 7 post 
orthotopic injection.  N/A; one mouse orthotopically injected with Clone 2 cells had a 
single small lung metastasis that did not appear in all three serial sections that were 






 Clone 1 Clone 2 
   
Tumor Histology Adenosquamous 
Carcinoma 
Sarcomatoid>Adenocarcinoma 
   
 +Androgen    - Androgen  
   
Frequency of Lung 
Metastasis 
       7/8                    9/9 1/12 




   
Luminal Phenotype        5/5                 3/5  
CK8+/CK5(+/-)/TP63-   
   
Biphenotypic        2/5                 4/5  
CK8+/CK5+/TP63+   






F. Analysis of biphenotypic Clone 1 in androgen replete and deprived 
conditions 
The initial characterization of Clone 1 at passage 4 demonstrated mostly double-
positive CK5+/CK8+ cells (Table 2).  As Clone 1 was cultured in vitro, CK5 expression 
decreased.  At passage 25, Clone 1 cultures consisted of 95% CK8+/CK14+/CK5- cells 
and 5% CK8+/CK14+/CK5+ cells, and quantitative PCR analyses of the same culture 
revealed expression of luminal (Krt18) and basal (Krt14 with low levels of Krt5) 
cytokeratins but not the definitive basal marker TP63.  Other basal/progenitor-associated 
markers such as Notch1, Sox2, and Itga6 were expressed (Fig. 5A).  Western blot 
analyses showed high constitutive levels of pAKT, detectable androgen receptor, and no 
detectable TP63 (Fig. 5B).  
Clone 1 subcutaneous tumors displayed adenocarcinoma histology and AR 
expression, two characteristics of human androgen-dependent prostate cancer.  To 
analyze androgen-dependent growth and development of the castrate-resistant phenotype, 
Clone 1 orthotopic tumor growth was performed in androgen replete conditions and in 
conditions that mimic patient treatment regimens giving rise to castrate-resistant prostate 
cancer.  Specifically, prior to orthotopic injections of Clone 1 cells, mice were castrated 
and implanted with testosterone pellets.  Orthotopic tumor growth was detected with in-
vivo bioluminescent imaging, usually between 4 and 6 weeks after inoculation.  At 7 
weeks post injection, mice were randomized into two cohorts.  Testosterone pellets were 
removed from half (n=9), while the remaining half (n=8) were reimplanted with new 
testosterone pellets.  Tumors were harvested upon death or morbidity of individual 
animals in both cohorts.  The removal of subcutaneous androgen pellets usually led to a 
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temporary halt in orthotopic tumor growth and a reduction in tumor mass as assayed by 
in-vivo bioluminescent imaging and by manual palpation.  Androgen deprivation led to a 
survival benefit as the mice in which the testosterone pellets had been removed survived 
up to 15 weeks post injection, while all of the androgen replete mice were moribund by 
week 9 post injection (Fig. 7A).  In addition, quantitative PCR analyses of RNA extracted 
from tumors revealed in androgen deprived mice loss of androgen-dependent gene 
expression as shown for Nkx3.1 and Msmb in Fig. 7B. 
Clone 1 orthotopic tumors grown in an androgen replete environment were 
composed of both CK8+ adenocarcinoma and TP63+ basal/squamous carcinoma 
components, demonstrating biphenotypic differentiation (Fig. 6).  Synaptophysin 
expression in both adenocarcinoma and basal/squamous carcinoma was heterogeneous.  
In androgen deprived tumors there were often foci of fibrosis and chronic inflammation, 
indicative of tumor regression.  However, Ki-67 immunohistochemistry identified 
multifocal regions of proliferation consistent with androgen independent tumor growth 
(data not shown).  Interestingly, the histological phenotypes of the androgen deprived 
tumors were similar to the androgen replete tumors with the exception of the amount and 
distribution of androgen receptor, which is discussed below (Fig. 8).  These data show 
that androgen deprivation of established tumors did not lead to the selective survival of 













 Clone 1 orthotopic prostate carcinomas.  A) Androgen pellets were either 
replenished (+Andro) or removed (-Andro) at seven weeks post orthotopic injection. 
Animals were removed from study when moribund.  B)  RNA samples extracted from 
Clone 1 tumors grown in androgen replete (n=5) or deprived (n=5) animals 
were assessed for Nkx3.1and Msmb expression levels by QRT-PCR.  Samples were 
normalized to GAPDH.  The androgen deprived tumors came from orthotopically 
injected mice that were euthanized between 19 and 33 days following the removal of 





Figure 8.  AR expression in Clone 1 orthotopic prostate carcinoma, recipient control 
prostate, and lung metastasis.  Recipient nude mice had androgen pellets replenished  (+ 
Andro): panels A,B,C or removed (-Andro): panels D,E,and F at week 7 post orthotopic 
injection.  The tumor shown was taken from a mouse that survived 20 days after the 
androgen pellet was removed.  A)  Recipient dorsal prostate showing expression in 
epithelial cells and occasionally in stromal cells (arrow).  B)  Androgen replete orthotopic 
carcinoma harvested 50 days post orthotopic injection  demonstrating strong nuclear 
expression and occasional reduced or absent expression (arrow).  C)  Lung metastasis 
from same mouse as in B.  AR expression  was primarily cytoplasmic with a granular 
appearance.    AR expression decreased in D) control (recipient) nude mouse prostate, E) 
adjacent orthotopic carcinoma, and F) lung metastasis.  All images taken at 400X, scale 





G. Clone 1 metastases 
Of interest, Clone 1 metastasized to the lungs in 9/9 androgen-deprived mice and 
in 7/8 androgen-replete mice (Table 3, see Supplemental Table 1). Lung metastases were 
immunophenotyped in five animals each from androgen-deprived and androgen-replete 
conditions. There was phenotypic cellular heterogeneity within individual metastases and 
among different metastases in the same mouse (see Supplemental Table 1).  All 
metastases contained CK8+ cells and displayed adenocarcinoma or an 
undifferentiated/solid carcinoma morphology.  However, some metastatic colonies 
contained TP63+ cells while others did not.   There was an observable phenotypic 
variability in lung metastases comparing androgen deprived and androgen replete 
conditions, shown in Table 3 as a fraction of mice harboring at least one metastatic lesion 
of the indicated phenotype.  Quantification of total metastases with respect to 
Immunophenotype demonstrated a statistically-significant increase in the total number of 
metastases containing TP63+ cells in androgen deprived mice (see Supplemental Table 
1).  Therefore, it appears that androgen deprivation effected either the selection of or 
differentiation of metastasis-initiating cells.  The number of lung metastases per mouse 
was not statistically different as a result of androgen deprivation (see Supplemental Table 
1) although this may be due to prior metastatic seeding and the presence of a significant 
tumor burden at the time of androgen withdrawal.  
An interesting phenotypic difference between primary tumors and lung metastases 
was observed with respect to AR staining patterns. Androgen-replete orthotopic 
carcinomas displayed heterogeneous nuclear AR levels, ranging from high levels to 
significantly reduced levels and occasional nuclei with undetectable AR (Fig. 8).  
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Remarkably, lung metastases that developed in animals with implanted testosterone 
pellets had minimal levels of nuclear AR as compared to the primary tumors, implying 
distinct AR-dependent signaling in primary tumors as compared to metastases, even 
under androgen replete conditions (Fig. 8C). As expected for androgen deprivation, 
nuclear AR levels in orthotopic tumors and in nude mouse recipient prostates were 
markedly reduced, accompanied by an increase in granular cytoplasmic labeling (Fig. 
8D-F).  Androgen deprived lung metastases usually had overall reduced levels of total 
AR, with minimal to undetectable nuclear AR levels and low granular cytoplasmic 
expression levels.   These data suggest that the metastatic cells have a distinct and 
















Supplemental Table 1.  The number and phenotype of lung metastases in individual 




All lung metastases were counted as detailed in the materials and methods.  
Immunohistochemistry for CK8, CK5, and TP63 were performed on sequential serial 
sections from 5 androgen replete (+Androgen) and 5 androgen deprived (-Androgen) 
mice.  Individual lung metastases were scored as being either luminal phenotype: cells in 
the metastasis contain CK8 and/or CK5 and are negative for TP63, or being 
biphenotypic: all cells in the metastasis contain CK8 and/or CK5 and at least one cell is 
positive for TP63.  Androgen deprivation led to a statistically significant increase in lung 
metastases that were biphenotypic (p<0.0212, Fisher’s exact test). There was no 
significant difference in the number of lung metastases per mouse between the androgen 
replete and androgen deprived conditions (p=0.1576, unpaired t-test).  N: total number of 
lung metastases per mouse; ND: immunophenotype not determined. 
 
 
Mouse # N Luminal Phenotype 
(no TP63+ cells) 
Biphenotypic 
(TP63+ cells present) 
    
+Androgen    
    
1-4 2 2 0 
1-7 14 14 0 
1-8 2 2 0 
1-14 5 2 3 
1-17 5 4 1 
1-3 2 ND ND 
1-5 2 ND ND 
1-6 0 ND ND 
    
-Androgen    
    
1-1 9 0 9 
1-10 1 0 1 
1-11 7 5 2 
1-12 2 1 1 
1-13 11 11 0 
1-2 2 ND ND 
1-9 14 ND ND 
1-15 6 ND ND 




Loss of PTEN and loss of TP53 are common genetic aberrations in human prostate 









 model of prostate cancer is the time-dependent development of 
heterogeneous histologies.   This most likely reflects the synergistic effect of Pten and 
TP53 loss on increased prostate epithelial progenitor/stem cell self-renewal and 
differentiation plasticity. The significant intertumoral and intratumoral morphological 








 model has not 




 mice by us or by others [34].   
The tumor suppressor TP53 functions pleiotropically in cells to negatively regulate 
growth through a variety of mechanisms including increased senescence, which 









tumors[35].  More recently it has been appreciated that TP53 plays an important role in 
the proliferation and differentiation of stem/progenitor cells [35, 118, 119].  TP53 inhibits 
self-renewal in nontransformed and transformed somatic stem cells, and we have 
demonstrated that Pten/TP53 null prostate progenitors have significantly increased self-
renewal ability in vitro [116].  These data suggest that the rapid growth and aggressive 








 model is due not only to 
decreased senescence in bulk differentiated tumor cells but also to increased progenitor 
amplification.  
TP53 also suppresses pluripotency and cellular dedifferentiation in induced 
pluripotent stem (iPS) cells [119].  In neural stem cells, the combined effects of losing 
PTEN and TP53 lead to impaired differentiation, although loss of either gene alone is 
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model, at least some tumor initiating cells demonstrate multipotency and/or 
differentiative plasticity.  Upon orthotopic transplantation, clonally derived TP63-
negative Clone 1 cells gave rise to TP63+ basal and TP63-negative luminal phenotype 
tumor cells with focal neuroendocrine marker expression.  These data imply either the 
transformation of a bipotential progenitor or plasticity of a committed progenitor to 
dedifferentiate.   Lineage marking studies in normal prostates have demonstrated that the 
development of most TP63-negative luminal epithelial cells involves a TP63+ precursor 
[121].  However, studies of clonal, immortalized human prostate cancer cell lines are 
similar to the results described here [122].  That is, clonal human TP63-negative tumor-
derived cells gave rise to tumors containing cells of multiple lineages, including TP63+ 
cells.  Taken together, we suggest that TP53 loss of function in prostate cancer 
contributes not only to abnormal cell cycle control but also to increased differentiative 
plasticity of the tumor cells.  The origin of the increased plasticity may be stochastic or 
alternatively, may be a result of transformation of a progenitor that precedes TP63+ basal 
cells in lineage commitment. 
We also have presented evidence that sarcomatoid carcinomas develop from CK8+ 








 model. Given the previous 
observation that TP53 loss in the context of Pten deletion results in decreased senescent 
markers in carcinoma cells, it is of interest to note that the bypass of senescence and the 
acquisition of an EMT phenotype have been correlated [35, 123, 124]. In other model 
systems, loss of senescence was attributed to oncogenic signaling acting in concert with 
transcription factors such as TWIST and ZEB1 that are known to regulate EMT.  
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whether transcription factors that regulate sarcomatoid carcinoma development at late 
stages initially inhibit senescence in adenocarcinoma. 
We observed osteogenic elements in some primary sarcomatoid carcinomas and in 
almost all Clone 2 orthotopic carcinomas. Human sarcomatoid carcinoma of the prostate 
is a rare but aggressive disease with poor prognosis [125].  The human tumors share 
many histological characteristics with the mouse tumors described here.  These include 
diverse epithelial lineages, including basal and neuroendocrine phenotypes, as well as 
heterologous elements such as osteosarcoma and chondrosarcoma.  TP53 has been 
demonstrated to control the proliferation and differentiation of mesenchymal stem cells 
with loss of TP53 leading to accelerated differentiation toward osteogenic lineages [126].  








 epithelial cells 
predisposes EMT-derived mesenchymal cells to differentiate toward osteo- and/or 
chondrogenic cells.  
The development of a mouse model of prostate cancer metastasis is important given 








 animals with end-stage disease and bioluminescent imaging of 
transplanted tumor cells, we observed lympho-vascular invasion and circulating tumor 
cell/emboli in pulmonary capillaries.  However, we conclude that the deletion of Pten and 
TP53 in prostate epithelial cells is not sufficient to allow metastatic colonization. 
Sarcomatoid carcinomas were rarely metastatic from primary tumors or following 
orthotopic growth of Clone 2.  Similar invasive but non-metastatic phenotypes for mouse 
mammary EMT-phenotype tumors have been described [127].  Although the ability to 
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undergo EMT correlates with progression and metastasis in various experimental models, 
it is important to distinguish reversible, or transient, EMT from the apparently 
irreversible EMT that occurs in sarcomatoid carcinoma.  A reasonable hypothesis is that 
terminal mesenchymal differentiation that occurs in sarcomatoid carcinoma is associated 
with a loss of the ability to undergo a mesenchymal to epithelial (MET) transition that 
contributes to metastatic colonization.  
A significant finding was that Clone 1, which produces biphenotypic tumors 
containing adenocarcinoma and basal/squamous carcinoma, is highly metastatic, most 
likely as a result of additional acquired genetic or epigenetic alterations.  
Immunophenotypic analysis of Clone 1 lung metastases demonstrated that they were 
either of a transit amplifying/luminal phenotype (CK8+/ CK5(+ /-)/ TP63-) or were 
biphenotypic, containing metastases with both TP63+ and TP63- cells. The relative 
abundance of these two metastatic phenotypes changed depending upon the androgen 
status of the mouse, with an increased percentage of biphenotypic metastases in androgen 
deprived animals (Table 3 and see Supplemental Table 1).  This suggests that androgen-
deprivation in this model selects for the growth and/or differentiation of cells with basal 
lineage commitment.  Although human prostate cancer metastases rarely contain TP63+ 
cells, the demonstration that metastasis-initiating cells have differentiative plasticity 
driven by androgen deprivation suggests the possibility that a related mechanism is a 
contributing factor to the development of castrate-resistant prostate cancer.  Interestingly, 
metastases demonstrated reduced nuclear AR compared to most regions of the primary 
orthotopic tumor, and the role of AR-dependent signaling in metastatic colonization is of 
interest for future studies.  A clonal prostate carcinoma cell line with multi-epithelial 
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lineage differentiation potential and a high metastatic rate will be useful for studying the 
molecular mechanisms driving androgen independent growth and prostate cancer 
metastasis. 




mice [B6.D2-Tg(Pbsn-Cre)4Prb, #01XF5] were obtained from the Mouse 










) were obtained from Anton Berns [128] 
and Luciferase + (FVB.Luc
+























Animals were bred, housed, and used in accordance with the Policy on Humane Care and 
Use of Laboratory Animals (Office of Laboratory Animal Welfare, NIH, Bethesda, MD).   
The following primer sets were used to detect the transgenes for the purposes of 






 R: 5’-AAGTTTTTGAAGGCAAGATGC-3’;Pb-Cre4 01: 5’-
ACCAGCCAGCTATCAACTCG-3’ and Pb-Cre4 02: 5’-
TTACATTGGTCCAGCCACC-3’.  This primer set was combined with Pb-Cre4 03: 5’-
CTAGGCCACAGAATTGAAAGATCT-3’ and Pb-Cre4 04: 5’-
GTAGGTGGAAATTCTAGCATCATCC-3’ to detect the wild type IL-2 allele that 
served as an internal control. Luc F: 5’-CCAGGGATTTCAGTCGATGT-3’ and Luc R: 
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5’-AATCTGACGCAGGCAGTTCT-3’. For all primer pairs, the thermocycler was run 
for 35 cycles with an initial 94C incubation for 3 minutes followed by 94°C melting (30 
seconds), 60°C annealing (1 minute), and 72°C extension (1 minute).  PCR products were 
run on a 1.5% agarose gel. 
Orthotopic Transplantation  
Single cell suspensions of primary prostate tumor cells from the dorsal and ventral 






 mice were prepared and injected into the 
dorsal prostate as described [116]. For orthotopic injection of cell lines, 750,000 cells 
resuspended in 10 l of prostate harvest media were injected into one of the anterior 
prostatic lobes of recipient nude mice.  Orthotopically injected nude mice were manually 
palpated weekly and imaged with the Xenogen Ivis (Caliper Life Sciences, Mountain 
View, CA) bioluminescent imaging system every two weeks as described [129].  Mice 
were euthanized upon signs of morbidity and/or when distended urinary bladders 
(indicative of urinary obstruction by prostate tumors) were easily palpable.  In order to 
test for androgen independent growth, the transplant recipient nude mice were castrated 
through an abdominal incision at the time of orthotopic injection and a 90-day release 
5mg testosterone pellet (Innovative Research of America, Sarasota, FL) was implanted 
subcutaneously in the cervical region.  Mice were randomized into two groups at week 
seven post orthotopic injection.  One group (n=9) had the subcutaneous testosterone 
pellets removed, and the other group had the androgen supply replenished by 





Derivation of wild type basal cell line 
The prostatic lobes from wild type mice were dissected from the urogenital tracts and 
prepared as described [116] except that the tissue digestion was stopped at the organoid 
stage before the trypsin digestion.  The organoids were washed once with PBS and 
resuspended in WIT-P medium (Stemgent, San Diego, CA), passed several times through 
a 19-guage needle, and plated into a 6-well Primeria plate (BD Biosciences, San Jose, 
CA).  The cells were passaged every 7 days for 6 passages.  The resulting established cell 
line was composed of morphologically uniform cells, and 100% of the cells expressed 
CK5 but not CK8 as determined by both flow cytometry and immunofluorescence. 
Derivation of Clonal Cell Lines  
Orthotopic carcinomas were aseptically harvested and washed briefly in sterile 
prostate harvest media DMEM (Invitrogen) supplemented with 10% fetal bovine serum, 
1% penicillin/streptomycin (Invitrogen), gentamycin (Lonza, Walkersville, MD): 300 l 
of a 50mg/ml solution/500ml, and amphotericin B (Lonza): 30 l of a 250ug/ml 
solution/500ml.  A 2-3mm cube of the tumor was minced and divided into 3 aliquots.  
Each aliquot was placed in a 10-cm Primeria tissue culture dish containing one of the 
three following medias: 1) PrEGM media (Lonza) containing 5 X 10
-9
M 
dihydroxytestosterone (Steraloids Inc., Newport, RI) referred to hereafter as 
PrEGM/DHT, or 2) PrEGM/DHT, 5% fetal bovine serum, and 5% 3T3 conditioned 
media, or 3) PrEGM/DHT and 5% 3T3 conditioned media.  3T3 conditioned media was 
produced by incubating 3T3 fibroblasts in prostate harvest media for 2 days.  The 
conditioned culture media was collected, clarified, filtered through a 0.4m filter, and 
stored at   -80C until use. 
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Cultures were incubated for one week or until there was growth on the dish, at which 
time cells were washed, trypsinized, and passaged two times before being plated at serial 
dilutions onto 10-cm Petri dishes. Cell cultures were maintained in the same culture 
media throughout the procedure.  Single well-spaced colonies demonstrating an epithelial 
morphology were harvested using gene choice cloning rings (PGC Scientific Corp., 
Frederick, MD) and placed into a single well of a 24 well Primeria plate. On average, less 
than 10% of colonies were capable of expansive growth and establishment.  Between 
passages 4-5, double immunofluorescence was performed for CK5/CK8 and 
CK8/vimentin.  Clones that demonstrated detectable CK5-/CK8-/vimentin+ cells, or 
greater than 1% CK8+/vimentin+ cells were excluded from further analysis.   Forty 
clonal cell lines were produced from 6 separate orthotopic tumors.  Nine of these cell 
lines, derived from 4 separate orthotopic tumors, were selected for tumorigenesis assays.  
Clone 1 was grown in PrEGM/DHT with 5% serum and 5% 3T3 conditioned media.  
Clones 2,3,4,5,7, and 9 were grown in PrEGM/DHT.  Clone 8 was grown in 
PrEGM/DHT with 5% 3T3 conditioned media.  
Subcutaneous tumorigenesis assay 
Single cell suspensions (1 X 10
6
) of clonal cell lines were injected subcutaneously 
with or without Matrigel
TM
 (BD Biosciences, San Jose, CA) into the flank region of nude 
mice (n=3 mice per cell line, with 3 tumors injected with matrigel and 3 tumors injected 
without matrigel).  Cells were resuspended and injected in 200 l of prostate harvest 
media. For the contralateral flank, the cells were resuspended in a mixture of 100 l of 
prostate harvest media and 100 l of Matrigel
TM
.  Subcutaneous tumors were harvested 




Primary prostate, subcutaneous, and orthotopic tumors were harvested and fixed with 
4% paraformaldehyde overnight, rinsed well in PBS, and transferred to 70% ethanol prior 
to standard histological processing, sectioning and staining (Histoserve Inc., 
Germantown, MD).  All prostates were sectioned as described [33], allowing for the 
examination of all prostatic lobes, the seminal vesicles, bladder, and urethra.  Several 
sections of the tumor, two sections through each lung lobe, and the sublumbar lymph 
nodes were placed together on the same slide.  For the purpose of histopathological 
analysis of disease progression, for each mouse, two H&E sections separated by 200 m 
were analyzed.  For the purposes of imunophenotyping the lesions, sequential serial 
sections were used for all immunohistochemical staining.  Two serial sections (separated 
by 200 m) of the liver, kidneys, spleen, brain, head, and decalcified longitudinal 
sections of the lumbar spine as well as fore and hind limbs were analyzed from each 
animal to assay for metastasis.  All slides were analyzed blindly and histopathological 
analysis was done by a board certified veterinary pathologist (P. Martin and M. 
Simpson). To quantify the percentage of orthotopic tumor area with a certain histological 
pattern, the area was estimated by using the number of 200X fields comprised by the 
particular histological pattern/total 200X fields analyzed, averaged over the two 200 m 
step sections. Bright field images were taken using an upright Zeiss Axioplan 
microscope.   
Immunohistochemistry  
Unstained slides were deparaffinized, and antigen retrieval was performed in a citrate 
buffer (DAKO targeted antigen retrieval solution) in a steamer at 100°C for 15 min, 
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followed by a 15 min incubation at room temperature.  Blocking was performed with 
Cyto Q Background Buster reagent (Innovex Biosciences, Richmond, CA) for 30 min at 
room temperature for rabbit primary antibodies, and for 1hr for mouse primary 
antibodies.  Primary antibody incubation was performed overnight at 4°C, followed by 
secondary antibody incubation at room temperature for 30 min. Secondary goat anti-
rabbit biotinylated IgG (E0432), and goat anti-mouse biotinylated IgG (E0433), used at 
1:200 dilution were from Dako (Carpinteria, CA).  The ABC peroxidase kit (Vector 
Laboratories, Burlingame, CA) was used followed by DAB (Dako) for chromagen 
visualization. All slides were counterstained with hematoxylin.   Primary antibodies and 
the concentrations used are as follows.  The following primary antibodies were obtained 
from Abcam (Cambridge, MA): anti-Ki-67 (ab15580), 1/600; anti-CK8 (ab59400), 1:50; 
anti-synaptophysin (ab52636), 1:250; anti-Chromogranin A (ab15160), 1:10,000; and 
anti-PTEN (ab9559), 1:100. Additional antibodies were anti-CK5, 1:1000, from Covance 
(PRB-160P),San Diego, CA; anti-TP63, 1:400, from Millipore (MAB4135), Billerica, 
MA; anti-AR (sc-816), 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA. The 
following antibodies were obtained from Cell Signaling (Danvers, MA): anti-E-cadherin 
(3195), 1:100; anti-pAKT (9271), 1:50; anti-TP53 (2527), 1:250, and anti-Slug (9585).  
At least 3 tumors from each experimental group (primary tumor, orthotopic transplant of 
primary tumor cells, and clonal orthotopic tumors both +/- androgen) were analyzed for 
immunohistochemical phenotyping. 
Immunofluorescence  
    Double immunofluorescence was performed on tissue sections using the same protocol 
as used for IHC with the following exceptions: The secondary antibodies were Alexa 
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Fluor 488 conjugated goat anti‐mouse IgG (A11001) and Alexa Fluor 586 conjugated 
goat anti‐rabbit IgG (A11011), 1:200,  (Invitrogen, Carlsbad, CA).  Slides were mounted 
with vectashield hard mount with DAPI (Vector Laboratories, Burlingame, CA).  The 
same primary antibodies at the concentrations indicated were used as for 
immunohistochemistry with the following exceptions: anti-cytokeratin 8 (CK8), 1:400 
from Covance (MMS-162P), San Diego, CA; anti-vimentin, 1:50 from Santa Cruz (sc-
7557), Santa Cruz, CA; anti-smooth muscle actin, 1:100, Abcam (ab5694), Cambridge, 
MA.  For immunofluorescence of cell lines grown in vitro, adherent cells were fixed in 
4% paraformaldehyde (PFA) in PBS for 10 min, followed by permeabilization with 0.5% 
Triton X‐100 in PBS for 2 min. Non‐specific sites were blocked by incubation in 2% 
BSA in PBS for 30 min.  Cells were then incubated overnight at 4°C with the specified 
primary antibodies in 2% BSA/PBS.  Cells were washed three times with PBS containing 
0.1% Tween‐20, incubated with Alexa Fluor 488 conjugated goat anti‐mouse IgG and 
Alexa Fluor 586 conjugated goat anti‐rabbit (1:200) in 2% BSA for 30 min at room 
temperature, and finally washed and mounted using the anti‐fade reagent Fluoro‐gel II 
with DAPI.  Fluorescent images were captured using a Zeiss Observer.Z1 laser confocal 
microscope and an upright fluorescent Zeiss Axioplan microscope.  In order to estimate 
the number of cells expressing CK8/CK5 or CK8/vimentin, two micrographs were taken 
at 200X for each combination of markers and the percentage of positive cells were 
counted and data was reported as the average of the two micrographs. 
Reverse Transcriptase PCR   
The following primer sets were used to detect mRNA for the purposes of assaying 
gene expression: Nkx3.1 F: 5’-GGAGAGGAAGTTCAGCCATC-3’ and  
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Nkx3.1 R: 5’-TGGCAAAGACAATGGTGAGT-3’; Msmb 
 F: 5’- CACCTGCTGTACCAACGCTA-3’ and Msmb R: 5’-  
CAACTCGACAGGTCTTCCCT-3’; Pten F: 5’-TTGAAGACCATAACCCACCA-3’ 
and Pten R: 5’-TTACACCAGTCCGTCCCTTT-3’; TP53 F: 5’-
TGGTGGTACCTTATGAGCCA-3’ and  TP53 R:  5’-AGGTTCCCACTGGAGTCTTC-
3’; Cdh1 F: 5’-GAC AACGCTCCTGTCTTCAA-3’ and Cdh1 R: 5’-
ACGGTGTACACAGCTTTCCA-3’; Krt5 F: 5’-AACGTCAAGAAGCAGTGTGC-3’ 
and Krt5 R: 5’-TCCAGCTCTGTCAGGTTGTT-3’; Krt19 F: 5’-
TATGAGATCATGGCCGAGAA-3’ and Krt19 R: 5’-CGTGACTTCGGTCTTGCTTA-
3’; Krt18 F: 5’- CTGGTCTCAGCAGATTGAGG-3’ and Krt18 R: 5’-
CTCCGTGAGTGTGGTCTCAG-3’; Krt14 F: 5’-GATGACTTCCGGACCAAGTT-3’ 
and Krt14 R: 5’-TGAGGCTCTCAATCTGCATC-3’; TP63 F: 5’-
CAGTCAAGGACTGCCAAGTC-3’ and TP63 R: 5’-CATCACCTTGATCTGGATGG-
3’; Itga6 F: 5’-ACGGTGTTTCCCTCAAAGAC-3’ and Itga6 R: 5’-
GAAGAAGCCACACTTCCACA-3’; Vim F: 5’-AAACGAGTACCGGAGACAGG-3’ 
and Vim R: 5’-TCTCTTCCATCTCACGCATC-3’; Acta2 F: 5’-
TTTCATTGGGATGGAGTCAG-3’ and Acta2 R R: 5’-
CCTGACAGGACGTTGTTAGC-3’; Cdh2 F: 5’-ATGCCCAAGACAAAGAAACC-3’ 
and Cdh2 R: 5’-CTGTGCTTGGCAAGTTGTCT-3’; Sox2 F: 5’-
ATGCACAACTCGGAGATCAG-3’ and Sox2 R: 5’-TATAATCCGGGTGCTCCTTC-
3’;  Sox9 F: 5’-CTCCGGCATGAGTGAGGT-3’ and Sox9 R: 5‘-
GCTTCAGATCAACTTTGCCA-3’; Notch1 F: 5’-TGGAGGACCTCATCAACTCA-3’ 
and  Notch1 R: 5’-GTTCTGCATGTCCTTGTTGG-3’; Myc F: 5’- 
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TTCTCTCCTTCCTCGGACTC-3’ and Myc R: 5’- TCTTCTTCAGAGTCGCTGCT-3’; 
Gapdh F: 5’- CAGAACATCATCCCTGCATC-3’ and Gapdh R: 5’- 
CTGCTTCACCACCTTCTTGA-3’.  For reverse transcription, 3ug of total RNA was 
used with the SuperScript III kit (Invitrogen, Carlsbad, CA).  The amplification step used 
the SYBR green PCR master mix (Applied Biosystems, Bedford, MA).   For all primer 
pairs, the thermocycler was run for 40 cycles with an initial 95°C incubation for 10 
minutes, followed by 95°C melting  for 15 seconds, 55°C annealing  for 30 seconds, and 
72°C extension for 30 seconds. 
Western Blotting 
For protein detection, the following primary antibodies at the indicated 
concentrations were used in an overnight 4C incubation: anti-rabbit CK8 (Abcam, 
ab59400), 1/1000; anti-rabbit AR (Millipore, #06-680), 1/500; anti-rabbit p-AKT (Cell 
Signaling, #4060), 1/1000;  anti-rabbit AKT (Cell Signaling, #4691), 1/1000; anti-mouse 
TP63 (Millipore, NAB-4315), 1/500; anti-mouse GAPDH (Novus Biochemicals, 
Littleton, CO: NB300-221), 1/4000.  Secondary antibodies (1:2000) were anti-rabbit IgG 
(#386325) or anti-mouse IgG (#381254) (GE Healthcare, Piscataway, NJ), incubated at 





Chapter 3: Increased Total and Mitochondrial-Associated Hexokinase II Provides A 
Metabolic Adaptation to Growth and Survival in Androgen Deprived Conditions 
I. Abstract 
Background. PTEN and TP53 loss are common molecular alterations in human castrate-
resistant prostate cancer.  We used a mouse model of Pten and Tp53prostate carcinoma to 
investigate the metabolic changes that occur with the development of castrate-resistant 
disease.    
Methods.  Castrated nude mice with subcutaneous testosterone pellets were 




 mouse prostate carcinoma cell line. 
Half of the mice had removal of testosterone pellets at 4 weeks post injection.  A broad 
spectrum metabolomic screen was performed on the resulting tumors to identify potential 
differences in energy metabolism associated with androgen independent growth.  Gene 
expression analysis and direct enzyme activity measurements were used to investigate 
differences in the transcription, activity, and cellular distribution of key metabolic 
enzymes.  2-deoxyglucose treatment and a competitive peptide inhibitor of HK II-
mitochondrial binding were used to compare the ability of the parental and ARKD cell 
lines to proliferate under metabolic stress.  Human tissue microarrays of primary and 
metastatic prostate cancer were immunostained with HK II to validate our findings of 
increased HK II as a metabolic adaptation to survival in androgen depleted conditions.   
Results.  The metabolomic screen identified depletion of carbohydrates, increased 
glycogen breakdown products, and an increase in lactate in androgen deprived relative to 
androgen replete tumors, suggesting an increased reliance on glycolysis in androgen 
depleted conditions.  mRNA expression analysis showed increased transcription of genes 
involved in glycolysis, TCA cycle, glycogen metabolism, and PPP in androgen deprived 
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tumors.  Enzyme activity assays showed increased cytoplasmic and mitochondrial-
associated HK activity in androgen deprived tumors relative to androgen replete tumors.  
Quantitative dual color IHC confirmed that HK II expression was increased in the 
castrate resistant tumors in both proliferating and non-proliferating cells.  This increased 
mitochondrial associated HK II allowed for increased survival in low glucose conditions 
(2-deoxyglucose treatment) as well as increased ability to withstand the negative effects 
of the competitive inhibition of HK II-mitochondrial binding.  HK II 
immunohistochemistry demonstrated a large increase in HK II expression in human 
metastatic CRPC relative to the low grade primary tumors. 
Conclusion.  These findings suggest that increased total and mitochondrial associated 
HK II is one metabolic adaptation that can promote androgen independent growth in 
prostate carcinoma, and is responsible for increased carbohydrate utilization in androgen 
deprived tumors.  Increased total and mitochondrial associated HK II provides for 
increased resistance to metabolic stress in androgen deprived tumors, and provides 
evidence for the selective advantage of increased total and mitochondrial HK II in vivo.  
This increased HK II-mitochondrial association provides an additional potential target for 
the treatment of castrate resistant prostate cancer.  
 
II. Introduction  
Despite current advances in prostate cancer treatment most cases of castrate resistant 
prostate cancer (CRPC) remain ultimately terminal.  Several mechanisms have been 
proposed and confirmed, by which prostate cancer cells evade the first line androgen 
deprivation therapy including: increased androgen receptor expression, AR gene 
amplification, increased utilization of adrenal androgens, and intra-tumoral 
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steroidogenesis, as well as others [13]. These mechanisms help to explain how tumor 
cells are able to maintain androgen dependent signaling networks despite minimal levels 
of circulating androgens.  Metabolic alterations may also play a role in prostate cancer 
progression and recent research [130-139] has revealed changes in several metabolic 
pathways.  However, there is still a large degree of uncertainty regarding the metabolic 
changes associated with the development of CRPC.   The large degree of genotypic and 
phenotypic heterogeneity observed in primary tumors and metastases reflects the 
numerous mechanisms by which prostate cancer cells adapt to evade androgen 
deprivation therapy, and contributes to the ultimate treatment failure of CRPC metastatic 
disease.  Determining the metabolic changes that evolve in the development of CRPC are 
critical and may allow more focused treatment options for patients with certain tumor 
genotypes and/or metabolic phenotypes.     
Although the genomics of prostate cancer are very heterogeneous, PTEN deletions 
and or mutations have been identified in up to 30% of primary tumors and 64% of 
metastatic prostate carcinomas [8, 9, 140]. An extensive genomic/mRNA expression 
analysis of primary and metastatic prostate cancer specimens by Taylor et. al.[10] showed 
altered PI3K signaling in approximately one half of the primary tumors and all of the 
metastases.  Thus PI3K-AKT pathway plays a significant role in prostate cancer 
progression, metastasis, and CRPC [11, 53, 141].  AKT activation is associated with 
increased glycolysis in via several mechanisms: including increased expression of 
glucose transporters, and expression and mitochondrial localization of HK II [83].  
Therefore it is reasonable to hypothesize that CRPC would have increased levels of 
glycolysis.  However, unlike most tumors which employ aerobic glycolysis as the major 
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bioenergetic pathway, primary prostate carcinomas rely on fatty acid B-oxidation [71].  
This feature is consistent with the low uptake of F18-FDG in PET imaging of most 
primary prostate carcinomas, the majority of which are low grade slow growing indolent 
tumors.  However, increased F18-FDG uptake has been demonstrated in androgen 
independent tumors, metastases, xenografts, and cell lines [77, 78, 142-145].   While 
there have been several studies that have addressed the role that androgens play in 
regulating prostate cancer metabolism in-vitro [146-149] there is still uncertainty as to the 
effects of androgen withdrawal on prostate cancer in-vivo.  More importantly, it has yet 
to be determined whether there are metabolic alterations that prostate tumor cells undergo 
that may serve as adaptations to survival in the androgen deprived environment. 
The metabolomic approach has been applied to prostate cancer and has successfully 
identified several biomarkers that are altered between normal and malignant tissue such 
as: decreases in citrate and polyamines, increased choline, glycerophospholipids, lactate, 
and several pathways of amino acid metabolism [139, 149].  This approach has also 
identified several biomarkers that correlate with disease progression and metastasis such 
as sarcosine, uracil, kynurenine, glycerol-3-phosphate, leucine, and proline [137].  
McDunn, et, al,2013 [134] used metabolomic screening of prostate cancer needle 
biopsies to develop a panel of metabolites that correlated with characteristics of disease 
aggressiveness: Gleason score, extra capsular invasion, and seminal vesicle/lymph node 
involvement.   The results indicated significant heterogeneity as there was stratification 
into 3 general metabolite “signatures” of aggressive prostate cancer.  These studies 
demonstrate the significant heterogeneity in prostate cancer metabolomics and highlight 
the utility of using mouse models with specific and common molecular lesions (ie: 
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Pten/Tp53 deletion) to identify mechanistic correlations between tumor genotype, 
metabolic signature, and disease progression.  In addition, these studies in general do not 
specifically address the metabolomic changes occurring with castrate resistant tumor 
growth.   
The increased aerobic glycolysis that is one of the characteristic changes in tumor 
metabolism (the Warburg effect) has been shown to be largely due to increased 
expression and mitochondrial localization of the first enzyme in glycolysis, HK II (HK II) 
which phosphorylates glucose to glucose-6-phosphate [60].  HK II binding to the outer 
mitochondrial membrane Voltage Dependent Anion Channel (VDAC) in tumor cells has 
been shown to inhibit the binding of pro-apoptotic factors Bax and Bad [59-61, 85, 91, 
92, 150] and blocking apoptosis.  The mechanism of this increased cytoplasmic and 
mitochondrial HK II has been demonstrated to be AKT dependent [39, 54, 57] making it 
a potential important metabolic adaptation in castrate resistant prostate cancer, which 
often demonstrates significant PI3K-AKT activation [10] However, there is a lack of 
research into the changes in HK II levels and cellular distribution that occur with the 
evolution of castrate resistant prostate cancer.    
The purpose of the current study was to determine whether there are changes in 
energy metabolism that accompany the evolution of androgen independent prostate 
cancer in-vivo.   We used a well characterized mouse model of human prostate cancer 
that is based on PTEN/TP53 deletion [40], two common molecular lesions observed in 
human androgen independent prostate cancer [10].  We show an increased reliance on 
carbohydrate metabolism as well as increased expression and activity of cytoplasmic and 
mitochondrial-associated HK II in androgen deprived tumors relative to androgen replete 
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tumors.  This metabolic adaptation afforded the androgen deprived cells an increased 
ability to withstand the metabolic stresses associated with a low glucose environment and 
treatment with a specific HK II-mitochondrial binding inhibitor.  In addition, we show 
that increased HK II levels correlated with human prostate cancer progression to CRPC 
and metastasis.  These data demonstrate that increased total and mitochondrial-associated 
HK II is an adaptive metabolic mechanism that can contribute to the evolution of 
androgen independent prostate cancer.   
III. Results 





clonal orthotopic tumors, however mice eventually succumb 
to androgen independent carcinomas. 
In order to investigate metabolic changes associated with the progression to 





deletions, two of the most common genetic alterations found 





 cell line (Referred to as “Clone 1”) derived from a prostatic 





previously [40].  Briefly, nude mice were injected with 500,000 Clone 1 cells under the 
thin capsule surrounding the anterior prostate gland.  At the time of surgery mice were 
castrated and either implanted with a subcutaneous 5mg testosterone capsule (low dose 
DHT experiment) or a 12.5mg testosterone capsule (high dose DHT experiment).  Mice 
in the low dose experiment had their DHT capsules either removed (n=9; referred to as 
androgen deprived), or replenished (n=8; referred to as androgen replete) at week 7 post 
orthotopic injection.  At this 7 week time point most of the tumors were able to be 
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palpated in anesthetized mice (approx. 2-5mm in diameter).  Mice were allowed to 
continue on study until signs of morbidity due to urinary obstruction from large prostate 
carcinomas.  Mice in the high dose DHT experiment had their 12.5mg testosterone 
capsule either removed (n=7) or remained intact (n=8) at week 4 before tumors were 
palpable, and were allowed to continue on study until signs of morbidity due to urinary 
obstruction were observed (Fig. 1A).   
In the low dose DHT experiment androgen replete mice (subcutaneous DHT 
capsule left intact) succumbed to disease faster (median 8 weeks) then the androgen 
deprived mice (median 11.5 weeks; p=0.0012) (Fig1A).  In the high dose DHT 
experiment androgen replete mice also succumbed faster (median 8 weeks) than the 
androgen deprived mice (median 10 weeks; p=0.0004) (Fig1A).  In the two androgen 
replete cohorts there was a trend in the higher dose DHT experiment towards increased 
rate of disease progression as compared to mice in the low dose DHT experiment 
(p=0.1272).  Similarly for the androgen deprived cohorts there was a trend towards 
increased rate of progression in the androgen deprived mice in the high dose DHT 
experiment (median 10wks) as compared to androgen deprived mice in the low DHT 
experiment (median 11.5wks; p=0.0633). 




 tumors [40] the 
histological appearance was adenocarcinoma admixed with a minority basal/squamous 
component (Fig1B).  Androgen deprivation led to an increased proportion of 
basal/squamous foci in the androgen deprived tumors (Fig1 C).  In both low and high 
dose androgen experiments there was frequent lymphovascular invasion, with the lung 
being the most common site of distant metastasis (Fig1D). The metastatic rate in the low 
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dose DHT experiment was 5.6 lung mets/mouse in the androgen replete mice and 6 lung 
mets/mouse in the androgen deprived mice (p=0.8952).  In the high dose DHT 
experiment the metastatic rate was 2.25 lung mets/mouse in the androgen replete mice 

















Figure 1.  Survival curves and histopathology of androgen replete and androgen deprived 




 prostate carcinomas. (A) Low dose 
DHT mice had a 5mg subcutaneous testosterone pellet implanted at the time of castration 
and orthotopic cell injection surgery.  The testosterone capsules were later removed from 
9 mice at week 7 post injection (arrow) when orthotopic tumors were easily palpable 
(bold line-androgen replete).  8 mice remained “intact” and were replenished with a new 
5mg testosterone capsule (broken line-androgen deprived).  All of the intact mice were 
removed from study by week 10 with large orthotopic tumors (>1cm diameter) and  
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failure/difficulty to urinate during palpation.  Removal of the testosterone pellet led to 
temporary tumor regression, and an approximate 2.5 week average increased survival 
time (p=0.0012). In the high dose DHT experiment mice were implanted with a 12.5mg 
subcutaneous testosterone pellet, which was then removed in 7 mice at week 4 post-
orthotopic injection (arrow), when most orthotopic tumors were not yet palpable.  With 
the high dose testosterone capsule all androgen replete (intact) mice were removed from 
the study by week 9 post injection.  Androgen deprivation in the high dose experiment 
led to a two week increase in median survival time (p=0.0004).  B) Orthotopic prostate 
tumors in androgen replete mice were primarily adenocarcinomas with occasional 
basal/squamous foci.  C) The tumors in androgen deprived mice had increased foci of 
basal/squamous differentiation (arrow heads).  D) Lung metastases were common in both 
androgen deprived and androgen replete mice.  The metastases were often surrounded by 
dense infiltrates of neutrophils (arrow heads).  Bar = 100um. 
 
B. A metabolomics screen identified significant differences in carbohydrate 
metabolism and the tricarboxylic acid cycle (TCA) in androgen deprived 
orthotopic tumors. 
In order to determine if there were significant metabolic differences between 
intact and androgen deprived orthotopic tumors we performed a broad spectrum 
metabolomic screen (Metabolomics™) on flash frozen orthotopic tumor samples 
collected at necropsy from both the low and high dose DHT experiments previously 
described.  Significant differences in carbohydrate metabolism and the TCA cycle were 
more common in the high DHT dose mice as compared to the low dose DHT mice.  Thus 
we focused our analysis on metabolic differences between androgen replete and androgen 
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deprived tumors in the high dose DHT experiment (Fig. 2A).  The most consistent 
changes in metabolism between intact and androgen deprived orthotopic tumors were 
decreases in carbohydrates that can be converted into glucose-6-phosphate for glycolysis.  
Tumor fructose, mannitol, and sorbitol levels were decreased in androgen deprived 
tumors compared to those measured in tumors from the androgen replete mice.  Evidence 
for glycogen metabolism to fuel glycolysis in androgen deprived tumors was 
demonstrated by significant increases in the glycogen breakdown products maltotetraose 
(2.86 fold increase) and maltotriose (7.93 fold increase) compared to the androgen replete 
tumors. 
In the TCA cycle there was a significant decrease in citrate levels in the androgen 
deprived tumors as compared to the androgen replete tumors (Fig 2B).  However, despite 
this decrease in citrate, the first intermediate in the TCA cycle, there were significant 
increases in the later intermediates: succinate, fumarate, and malate in the androgen 
deprived mice relative to the androgen replete mice.  Levels of aspartate and glutamate 
were also increased in the androgen deprived tumors relative to the androgen replete 
tumors suggesting replenishment of TCA cycle intermediates via anaplerosis, ie: 





















orthotopic prostate carcinomas .  A) Heat map depicting metabolic changes in androgen 
deprived orthotopic tumors relative to androgen replete tumors in several key energetic 
pathways.  Values indicate fold of change in androgen deprived tumors relative to 
androgen replete tumors.  Shaded cells indicate p≤0.05 (red indicates that the mean 
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values are significantly higher in androgen deprived tumors; green values significantly 
lower). Blue print indicates strong trend (0.05<p<0.10) for increase in androgen deprived 
tumors relative to androgen replete tumors.  Light green print indicate strong trend 
(0.05<p<0.10) for decrease in androgen deprived tumors relative to androgen replete 
tumors. 5mg DHT; Low dose DHT experiment: Androgen replete: n=7, Androgen 
deprived: n=6.  12.5mg DHT; High dose DHT experiment: Androgen replete n=7, 
Androgen deprived: n=6. B) Integrated model of metabolic changes in glycolysis and the 
tricarboxylic acid (TCA) cycle in high dose DHT experiment.  Blue indicates increase in 
androgen deprived tumors relative to androgen replete tumors, green indicates decrease in 
androgen deprived tumors relative to androgen replete tumors. 
 
 
In order to determine whether the metabolic changes associated with progression 
to androgen independent growth in our murine model are similar to those reported for 
malignant progression in human prostate cancer, we compared our results to several 
published reports of metabolic changes associated with progression in human prostate 





 orthotopic tumor model mirror those observed with progression in human 
prostate cancer specimens including: increased sarcosine[137], spermine [133], glutamine 
[133], glutamate [133], alanine [133], proline/hydroxyproline[137], uracil[137], and 
leucine [137] (Fig. 3).  However it should be noted that these studies on human prostate 























[DHT]        5mg             12.5mg                         5mg            12.5mg 
 DHT     +         -          +          -                      +          -         +         - 
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human prostate cancer specimens.  Values (y-axis) are scaled intensities representing 
relative biochemical amounts (Metabolon™).    DHT concentrations of 5mg = low dose 
androgen, 12.5mg = high dose androgen, DHT + = androgen replete tumors; - = androgen 
deprived tumors.  Androgen replete tumors are blue bars (CL1-AD) and androgen 
deprived tumors are red bars (CL1-AI).  Box and whisker plots represent: + = mean;          
central line in box = median; box represents upper and lower quartile above and below 
mean; whiskers represent maximum and minimum values (range); empty circles 
represent outliers.  
C. Androgen deprivation leads to upregulation of many genes involved in 
key energetic pathways related to carbohydrate metabolism 
In order to determine if there were transcriptional differences associated with the 
metabolomic differences observed in androgen deprived orthotopic tumors, we performed 
a focused metabolic gene expression analysis (Qiagen™) on tumors from the high dose 
DHT experiment.  The expression of several genes in each pathway: glycolysis, glycogen 
metabolism, TCA cycle, and pentose phosphate pathway were significantly increased in 
the androgen deprived tumors relative to the intact tumors (Fig 4).  In fact all of the 
significant changes were in the direction of increased expression in androgen deprived 










Figure 4.  Androgen independent growth leads to increased expression of many genes 
involved in carbohydrate metabolism. The Qiagen™ Glucose Metabolism RT-PCR array 
was used to analyze the expression of 84 genes involved in glycolysis, TCA cycle, 
glycogen metabolism/gluconeogenesis, and the pentose phosphate pathway.  Bars 
represent mean fold change in gene expression in androgen deprived orthotopic prostate 






D. Androgen deprivation in orthotopic tumors and Clone 1 cells in-vitro 
leads to increased cellular levels of hexokinase II 
Based on evidence from the metabolomics screen and gene expression analysis 
which suggested increased utilization of carbohydrates for energy metabolism in 
androgen deprived orthotopic tumors, we hypothesized that this would be accompanied 
by increased amounts and/or activity of Hexokinase enzyme activity, specifically HK II 
the major isoform responsible for the Warburg effect in most tumor cells [59].  Androgen 
deprived prostate carcinomas in this model have a large degree of heterogeneity in 
cellular proliferation with multifocal quiescent regions with low or no proliferation 
adjacent to rapidly proliferating regions with abundant nuclear Ki67 expression.  Thus, in 
order to quantify and compare cellular HK II levels in both proliferating and non-
proliferating regions of androgen replete and androgen deprived tumors we employed 
dual color immunohistochemistry.  Cytoplasmic levels of HK II were detected with DAB 
while nuclear Ki67 was detected with Impact™ NovaRed, allowing for the semi 
quantitative scoring of HK II levels in both proliferating and non-proliferating cells 
(0=negative, 1=minimal/mild, 2=moderate, 3=strong).  This dual color IHC demonstrated 
increased levels of HK II in both proliferating and non-proliferating cells in androgen 
deprived tumors relative to the androgen replete tumors (Fig 5).  In proliferating (Ki67+) 
tumor cells the average per cell HK II score was approximately 34% greater in androgen 
deprived tumors relative to androgen replete tumors (p<0.0001, Mann-Whitney U-Test).  
In non-proliferating (Ki67-) tumor cells the average per cell HK II score was 
approximately 17% greater in androgen deprived tumors vs. androgen replete tumors 
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(p<0.0001) (Fig 5G).  In both androgen replete and androgen deprived tumors the mean 
per cell HK II scores in proliferating cells were significantly higher than in non-
proliferating cells: 72% greater in androgen replete tumors and 92% greater in androgen 
deprived tumors (p<0.0001).  Thus androgen deprivation leads to a greater increase in the 
magnitude of HK II levels in proliferating cells vs. non-proliferating cells.  The frequency 
distribution of per cell HK II scores also reflected this significant increase in HK II levels 
in androgen deprived tumors, regardless of cellular proliferation status (Supplemental 
figure 1A).  We also employed an automated quantification (Using the Ariol™ 
Scanning/Analysis System) of the dual IHC to support and confirm the semi-quantitative 
histopathological scoring of increased HK II in androgen deprived tumors.  Linear 
regression analysis was used to compare the relationship between tumor region of interest 
(ROI) proliferation (%cells Ki67+) and ROI % area positive for HK II in androgen 
replete and androgen deprived tumors.  Each tumor was divided into 150um square ROIs 
so that the entire tumor was analyzed in a non-biased method.  This analysis revealed a 
positive linear correlation between ROI proliferation and HK II levels in both conditions, 
with a statistically significant (p<0.001) steeper slope in the androgen deprived tumors 
(supplemental figure 1B).  Thus when controlling for the reduced rate of cellular 
proliferation in androgen deprived tumors, they have a significantly higher level of HK 
II.  The effect of androgen deprivation on HK II levels in the clone 1 cells in-vitro was 
also assessed by western blot.  48 hours of androgen deprivation led to a significant 






Figure 5.  Dual color immunohistochemistry demonstrates increased HK II expression in 
androgen deprived orthotopic tumors relative to androgen replete tumors.  Androgen 
deprived tumors (A,B,C) and androgen replete tumors (D,E,F) both demonstrate 
increased HK II expression with increased proliferation (Ki-67), however the magnitude 
of this response is higher in androgen deprived tumors.  A) Androgen deprived tumors 
have a prominent increase in HK II expression in the higher proliferating regions at the 
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periphery of the tumors (arrow heads), 10X.  B) High HK II expression in peripheral 
tumor region with high proliferation, 40X.  C) Lower HK II expression in interior region 
of same tumor with no proliferating cells rate, 40X.  Note that the cytoplasmic HK II 
levels are higher in the non-proliferating region of the androgen deprived tumor than in 
the proliferating region of the androgen replete tumor (F).  D) Androgen replete tumors 
often have moderate increases in HK II expression at the tumor periphery (arrow heads), 
however the increase in HK II at the proliferating tumor periphery is not as prominent as 
in the androgen deprived tumors, 10X.  E) Moderately increased HK II expression at 
periphery of androgen replete tumor, 40X.  F) Low HK II expression in proliferating 
region in interior of same androgen replete tumor, 40X.  Note that several proliferating 
cells have no or minimal HK II expression, while the non-proliferating cells in the 
androgen deprived region in (C) have mild to moderate levels.  Dual color 
immunohistochemistry with anti-HK II: cytoplasmic (DAB) and anti-Ki-67: nuclear 
(ImmPACT NovaRED).  G) Increased relative amounts of cellular HK II  in androgen 
deprived (-Andro) orthotopic tumor proliferating and non-proliferating cells relative to 
the androgen replete tumor cells (+Andro).  Dual color immunohistochemistry was used 
to label proliferating cells as well as the levels of HK II.  For each orthotopic tumor 100 
Ki67+ cells and 100 Ki67- cells were randomly chosen and scored semi-quantitatively for 
cytoplasmic HK II levels (0=negative, 1=minimal/mild, 2=moderate, 3=strong).   In 
androgen deprived tumors (-Andro) there is a significantly higher HK II expression in 
both proliferating (Ki67+, p<0.0001) and non-proliferating (-Ki67, p<0.0001) tumor cells 
as compared to androgen replete (+Andro) tumor cells (Mann-Whitney U test).  H) 
Increased total cellular HK II in androgen deprived (-DHT) clone 1 cells (24hrs of 
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androgen withdrawal) relative to androgen replete cells (+DHT).  Mitochondrial inner 
membrane protein (50kDa) and porin (39kDa) used as protein loading controls to control 
for possible differences in mitochondrial amounts between androgen replete and 


























E. Androgen deprivation leads to increased total hexokinase enzyme activity 
in-vitro as well as in vivo, with increased levels in the mitochondrial cellular 
compartment. 
In order to determine if the observed increases in HK II enzyme expression were 
associated with increased enzyme activity levels, we performed direct total hexokinase 
enzyme activity assays on clone 1 cells grown in-vitro, as well as on the androgen replete 
and androgen deprived orthotopic tumors. We also fractionated the cells into cytoplasmic 
and mitochondrial compartments in order to investigate sub-cellular differences in 
hexokinase activity.  In clone 1 cells grown in-vitro, 48 hours of androgen deprivation led 
to significant increases in both cytoplasmic (p=0.0258) (Fig6A) and mitochondrial 
fraction total hexokinase activity relative to the androgen replete cells (p=0.003) (Fig6B).  
Regardless of DHT treatment the enzyme activity in the mitochondrial fraction was 
dramatically increased to approximately 6-7 fold of the levels in the cytoplasmic 
compartment (p<0.0001).  The orthotopic tumors also demonstrated significant 
differences in hexokinase activities between androgen replete and androgen deprived 
tumors (Fig6C).  The flash frozen tumor samples were fractionated into cytosolic and 
particulate fractions, as it was not possible to obtain pure mitochondrial fractions on the 
flash frozen tumors.  The cytosolic hexokinase activity was approximately 35% greater in 
the androgen deprived tumors (p=0.0308).  The particulate hexokinase activity was 
approximately 3.4 fold greater in the androgen deprived tumors, however there was a 
high degree of variability (p=0.1231).  As the activity of the first enzyme in glycolysis 
(Hexokinase) was significantly increased in the androgen deprived tumors, we then 
assayed the activity of pyruvate dehydrogenase the final enzyme in the pathway linking 
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glycolysis and the TCA cycle.  No significant differences were found between the 
pyruvate dehydrogenase activities of the cytosolic or particulate fractions of either the 
androgen replete or androgen deprived tumors (Figure 6D).  In order to confirm that the 
large increase in HK II activity in the particulate cellular fraction of the orthotopic tumors 
was due to mitochondrial associated-HK II, we performed dual labeling confocal 
microscopy on 4% PFA fixed paraffin embedded orthotopic tumors to co-localize HK II 
and mitochondrial porin, a component of the VDAC on the outer mitochondrial 











Figure 6.  Increased in-vitro and in-vivo cytoplasmic and mitochondrial or particulate 
hexokinase activity in androgen deprived tumor cells.  A) In-vitro 48 hours of androgen 
deprivation (-DHT) led to significant increases in both cytoplasmic (Fig 6A) and 
mitochondrial (Fig 6B) total hexokinase enzyme activity.  Note the large increase in the 
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magnitude of the mitochondrial levels as compared to the cytoplasmic levels.  Mean +/- 
S.D. C & D) Orthotopic tumor cytoplasmic and particulate hexokinase and pyruvate 
dehydrogenase enzyme activity in intact androgen replete  (+DHT; n=4) and androgen 
deprived (-DHT; n=7) mice.  Total enzyme activity was measured as an increase in 
optical density (O.D.) per mg total protein over a 45 minute colorimetric enzyme activity 
assay performed on the cytosolic and particulate cellular fractions.  There is a 
significantly higher mean (+/- S.D.) hexokinase activity in the androgen deprived 
cytoplasmic fraction (p=0.038) and a trend towards a higher activity in the particulate 
fraction (p=0.1231).  There is no significant difference in pyruvate dehydrogenase 
activity between the castrated and intact mice in either subcellular fraction.  E) Confocal 
microscopy confirming the mitochondrial localization of HK II at the outer mitochondrial 
membrane porin/Voltage dependent anion channel (VDAC).  Mouse anti-mitochondrial 
porin detected with goat anti-mouse-Alexa488 and rabbit anti-hexokinase II detected with 
goat anti-rabbit-Alexa568. 
 F. Androgen deprived cells have increased growth/survival under 
conditions of metabolic stress 
As androgen deprived tumors and clone 1 cells grown in-vitro have increased 
levels of HK II, we hypothesized that they would have a survival advantage when 
subjected to metabolic stress.  We used varying concentrations of 2-deoxyglucose in-vitro 
to metabolically stress the cells by simulating a low glucose environment.  The MTT 
assay was used to determine if there were differences in cell viability (growth and 
survival) after 24 hours of androgen withdrawal in 0, 0.125mM, 0.25mM, 0.5mM, and 
1mM of 2-deoxyglucose (Fig 7A).  In normal metabolic conditions with no 2-
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deoxyglucose there was no significant difference in viability between the androgen 
replete and the cells that were androgen deprived for 24hrs.  In 0.125mM 2-deoxyglucose 
there was an approximate 25% increase in viability in the androgen deprived cells 
(p=0.0085).  In 0.25mM 2-deoxyglucose there was an approximate 25% increase in 
viability in the androgen deprived cells (p=0.016).  In 0.5mM 2-deoxyglucose there was 
an approximate 33% increase in viability in the androgen deprived cells (p=0.016).  In 
0.5mM 2-deoxyglucose there was an approximate 32% increase in viability in the 
androgen deprived cells (p=0.0016).  In 1mM 2-deoxyglucose there was a trend towards 
increased viability in the androgen deprived cells (approximate 16% increase in cell 
viability), although this did not rise to the level of statistical significance (p=0.185). 
We also used a competitive peptide inhibitor of HK II-mitochondrial binding to 
test the hypothesis that androgen deprived clone 1 cells will have increased resistance to 
the HK II-mitochondrial inhibitor due to higher total and mitochondrial levels of HK II.  
We also used this specific inhibitor of HK II to test the hypothesis that HK II-
mitochondrial binding is necessary for optimal tumor growth. 12 hour incubation with 
two different concentrations of the HK II-inhibitor peptide demonstrated increased 
viability of the androgen deprived cells (Fig. 7B).  At 0.5uM [HK II-inhibitor] there was 
an approximate 22% greater growth/survival in the androgen deprived cells (p=0.0079), 
and at 1uM there was an approximate 21% greater growth/survival in the androgen 
deprived cells (p=0.0004).  The importance of the HK II-mitochondrial binding for 
optimal tumor growth regardless of androgen conditions was evident by the significant 
decrease in growth/viability at the 1uM concentration of the HK II-mitochondrial 











Figure 7.  Increased cell viability in response to metabolic stress in androgen deprived 
Clone 1 cells in-vitro.  A) Response to low glucose conditions (2-deoxyglucose treatment 
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for 24 hrs) in androgen replete (+DHT) and androgen deprived (-DHT) cells.  Androgen 
deprived cells had significantly increased viability at 0.125mM, 0.25mM, and 0.5mM 
concentrations of 2-deoxyglucose relative to androgen replete cells.  B) Response to HK 
II-mitochondrial binding competitive inhibitor in androgen replete (+DHT) and deprived 
(-DHT) cells.  Cells were treated for 12 hours with either 0.5uM or 1uM of the 
competitive peptide inhibitor bound to HIV-TAT protein to allow for cellular uptake, or a 
random TAT-control peptide.  At both concentrations of the inhibitor peptide there was 
significantly increased viability in the androgen deprived cells relative to the androgen 
replete cells.  At 1uM both androgen replete and androgen deprived cells had decreased 
survival as compared to TAT-control peptide, demonstrating the survival benefit of 
mitochondrial-bound HK II in prostate carcinomas. 
 G. Metastatic castrate resistant human prostate cancer has significantly 
higher levels of Hexokinase II than primary tumors 




 mouse model of castrate 
resistant prostate cancer led us to hypothesize that there will be increased levels of HK II 
in human CRPC as compared to primary androgen dependent tumors.  In order to test this 
hypothesis we performed HK II immunohistochemistry on two tissue microarrays, one 
containing 54 samples of primary prostate adenocarcinoma and the other containing 45 
samples from castrate resistant metastases.  The tissue cores were semi-quantitatively 
scored based on the relative number of cells expressing HK II as well as the intensity of 
the immunolabeling: (no expression = 0, minimal = 1, mild = 2, moderate = 3, strong =4).  
The metastatic tumors had a dramatic increase in HK II levels (p<0.0001, Mann-Whitney 
U test), as most metastases had strong levels of expression (Ave. Score = 3.7).  Most of 
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the primary tumors were negative with occasional ones having minimal HK II levels, and 
rare tumors having mild levels (Ave. Score = 0.24) (Fig8). 
 
 
Figure 8.  HK II levels in human prostate cancer primary and metastatic tumors.  Tumors 
were scored semi-quantitatively for HK II levels detected by immunohistochemistry on 
human prostate cancer tissue microarrays.  No expression = 0; minimal expression = 1; 
mild expression = 2; moderate expression = 3, strong expression = 4.   A) Normal 
 95 
 
prostate with no detectable HK II.  B) Low grade primary prostate adenocarcinoma with 
minimal cytoplasmic HK II expression.  C)  Primary prostate adenocarcinoma with mild 
cytoplasmic HK II expression.  D) Metastatic prostate carcinoma in unspecified lymph 
node with minimal cytoplasmic HK II.  E) Metastatic prostate carcinoma in periaortic 
lymph node with high levels of HK II.  F) Prostate adenocarcinoma bone metastasis in 
sacrum with high levels of HK II.   Note bone spicule within sacrum marrow cavity(*) 
with adjacent adenocarcinoma glands (arrow) with high levels of HK II.  G)  Comparison 
of HK II IHC score between primary and metastatic tumors.  Metastatic tumors have 
significantly higher levels of HK II than primary tumors (p<0.0001; Mann-Whitney U 
test)  
IV. Discussion 
In this study we demonstrate an association between the development of castrate 
resistant prostate cancer (CRPC) and increased total and mitochondrial-associated HK II.  
This relationship between increased HK II and CRPC was validated in human metastatic 
prostate cancer specimens, as well as in a mouse model containing genetic alterations, 
PTEN/TP53 deletions, commonly found in late stage human CRPC.  Thus we propose an 
adaptive metabolic mechanism by which increased total and mitochondrial-associated 
HK II provide a selective advantage to prostate tumor cells in the androgen deprived 
environment and contribute to the evolution of CRPC.  The adaptive significance of 
increased HK II was supported by a dramatic increase in HK II protein amounts in human 
metastatic/CRPC specimens relative to primary low grade prostate adenocarcinomas (Fig 
8).  This phenomenon was also reflected in the mouse model as there was increased HK 
II protein (Fig5) and enzyme activity in androgen deprived orthotopic mouse tumors as 
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compared to the androgen replete tumors in intact recipient mice (Fig 6).  As we were 
unable to reliably produce pure mitochondrial fractionation from the particulate cellular 
fractions of our flash frozen tumor samples, we confirmed the mitochondrial localization 
of HK II using confocal microscopy to demonstrate co-localization with mitochondrial 
porin, a component of the VDAC on the outer mitochondrial membrane (Fig6E), and the 
HK II binding site.  Mitochondrial localization was also confirmed in the parental cell 
line in-vitro, as producing pure mitochondrial fractions from cell pellets was possible 
(Fig6).  Indirect evidence supporting this adaptive mechanism was provided by a 
metabolomics screen that suggested an increased reliance on carbohydrate metabolism in 
the androgen deprived tumors relative to the androgen replete tumors (Fig2), as well as 
increased expression of many genes involved in glycolysis, glycogen metabolism, the 
TCA cycle, and the pentose phosphate pathway (Fig4).   
We confirmed the adaptive significance of increased total and mitochondrial HK II by 





prostate cancer cells (Fig5H), and this afforded them an increased ability to 




prostate cancer cells, which showed increased total and mitochondrial-associated HK II, 
were better able to survive the metabolic stress associated 2-deoxyglucose treatment, an 
inhibitor of glycolysis, than the same cells grown with DHT (Fig 7A).  Androgen 
deprived cells also had an increased ability to withstand the growth inhibitory effects of a 
competitive peptide inhibitor of the HK II-mitochondrial association, suggesting a 
survival benefit of increased levels of residual mitochondrial-associated HK II that is 
associated with androgen deprivation (Fig 7B).  Increasing concentrations of the HK II-
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prostate cancer cells regardless of androgen presence, demonstrating the survival 
benefit of HK II binding to the outer mitochondrial membrane (OMM).  However the 
androgen deprived cells with elevated HK II had significantly increased HK II inhibitor 
peptide dose-dependent growth and survival relative to the androgen replete cells.   These 
findings from the human prostate cancer specimens and our mouse model implicate 
increased HK II as an adaptive metabolic mechanism in CRPC.  The fact that virtually all 
of the human metastatic samples had high HK II expression despite presumed genetic 
heterogeneity suggests that this metabolic mechanism may represent a unifying 
phenomenon and evolve through a number of different genetic alterations.   
The most obvious adaptive significance of an increased total and mitochondrial HK II 
is an increased rate of glycolysis to fuel energy metabolism, as well as increased 
production of carbon precursors for anabolic processes such as nucleic acid synthesis via 
the pentose phosphate pathway and de-novo lipogenesis.  Increased glycolysis in the 
androgen deprived tumors relative to the androgen replete tumors is supported by the 
increased protein levels (Fig 5) and activity (Fig 6) of HK II which is the rate limiting 
step in glycolysis.  Increased glycolysis with androgen deprivation was also supported by 
the metabolomic data (Fig 2) which showed marked carbohydrate depletion and 
increased glycogen breakdown products.  In addition to the energetic benefit, increased 
ribose 5-phosphate with androgen deprivation suggests that increased glycolysis was also 
providing increased carbon precursors for nucleic acid production.  Increased FDG 
uptake in clinical PET imaging of CRPC metastases demonstrating an increased 
glycolytic flux [144] as well as our demonstration of increased HK II expression in 
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human metastatic lesions support the adaptive energetic benefit of increased carbohydrate 
utilization in CRPC.  Genetically engineered mouse models (GEMs) of cancer have been 
used to demonstrate that increased HK II expression is critical for tumor energy 
production, increased flux of glucose into the pentose phosphate pathway (PPP) for 
nucleic acid production, and flow of carbon precursors into the Tricarboxylic Acid Cycle 
(TCA) as acetyl-CoA and citrate [151].   
Our finding of decreased citrate provides preliminary evidence that in CRPC 
increased amounts of citrate are shuttled out of the mitochondria for de-novo lipogenesis 
in the cytoplasm.  The finding of increased succinate, fumarate, and malate with 
increased aspartate and glutamate in androgen deprived tumors relative to androgen 
replete tumors, is consistent with replenishment of the TCA cycle intermediates through 
anaplerotic reactions.   These anaplerotic reactions include glutaminolysis to replenish α-
ketoglutarate, and aspartate conversion into oxaloacetate (Fig 2B).  However, as 
metabolomic screening only gives a one time “snap-shot” of biochemical intermediate 
levels, rather than actual pathway flux, further research would be necessary to confirm 
these other interesting possible metabolic adaptations in CRPC.  The similarities between 
metabolites that were increased with the development of CRPC in our model vs. those 
observed to be increased with disease progression in human primary prostate cancer 
specimens (Fig 3) support the relevance of this mouse model for dissecting the metabolic 
and molecular mechanisms associated with prostate cancer progression and CRPC.   
Notably we identified that androgen deprived tumors, relative to androgen replete tumors, 
had increased sarcosine, spermine, and amino acid metabolites which parallel the 
findings demonstrated with disease progression in primary human prostate cancer [130, 
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134, 136, 137, 152], although in the human prostate cancer samples comparisons between 
androgen dependent and androgen independent (CRPC) disease were not made. In 
addition to providing a massive energetic and anabolic benefit through the coupling of 
glycolysis and oxidative phosphorylation at the outer mitochondrial membrane, the 
binding of HK II at the VDAC also provides protection against the initiation of apoptosis 
by blocking the binding of pro-apoptotic factors such as bad and bax [59-61, 85, 90-92, 
101, 102] Our study implicates this elegant pro-survival mechanism as one way that 
prostate cancer cells can evade the pro-apoptotic signals that occur with androgen 
deprivation.   The high amount of HK II bound to the mitochondrial membrane may even 
provide protection against apoptosis induced by drug treatments as well.   
Our finding of increased HK II in human metastatic CRPC, and increased total and 
mitochondrial HK II in our mouse model adds to the growing body of evidence 
supporting the importance of cancer metabolic adaptation through increased HK II levels 
and mitochondrial localization[58-61, 83-86, 88, 90-93, 100, 101, 151].  A potential role 
of PI3K-AKT signaling in promoting the mitochondrial-HK II association (Reviewed by 
Majewski, et al [102]) is likely in the Pten-/-Tp53-/-mouse model that  showed high 
levels of pAKT activation due to the removal of the inhibitory effects of Pten expression. 
It has also been shown that elevated HK II expression in GEM cancer models is driven by 




tumors in our study in 
addition to expressing large amounts of pAKT, also express high cytoplasmic and nuclear 
levels of pERK indicating that MAPK signaling may also play a role in metabolic 
adaptation to CRPC.  Blocking PI3K-AKT inhibits the HK II-mitochondrial association 
in human hepatocellular carcinoma cell lines [83].  In addition, these investigators 
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demonstrated that for human non-small cell lung cancer (NSCLC) and breast cancer 
clinical specimens, expression of HK2 via IHC on tissue microarrays was increased over 
adjacent normal tissues, and was positively correlated with increased pathological grade 
of the tumors as well as poor clinical outcomes.  The association of PI3K-AKT and p-
ERK/MAPK signaling in both human and mouse CRPC was also demonstrated by 
Kincade et. al, [11]. 
Several studies have shown that Pten loss with increased PI3K-ATK signaling is 
associated with CRPC in mouse models of prostate cancer as well as in human CRPC 
[11, 34, 40, 153-155].  The current study provides one specific metabolic mechanism that 
can explain adaptation to CRPC in the context of PI3K-pAKT and pERK-MAPK 
signaling: increased total and mitochondrial associated HK II.  This finding also provides 
a mechanistic explanation for the common imaging results found in primary low grade 
prostate cancer (low FDG-PET uptake), while metastatic lesions often have increased 
FDG uptake [144]  Indeed we showed that primary low grade prostate cancer rarely 
expressed HK II while most CRPC metastases had high levels of HK II (Fig 8).  
Exploiting the pro-survival metabolic mechanism of increased HK II may also have 
important implications for treatment of CRPC.  Inhibition of HK II-mitochondrial 
association with compounds such as 3-bromopyruvic acid has already shown efficacy 
against tumors in animal models [95-98].  Targeting prostate cancer glycolysis with the 
inhibitory 2-Deoxyglucose has also been attempted in human clinical trials [99] however 
the results were unfavorable.  Our results suggest that 2-Deoxyglucose treatment may be 
more effective when used at the initiation of androgen deprivation therapy, in order to 
inhibit the evolution of CRPC that we show is more dependent on glycolysis than 
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primary androgen dependent tumors.  As androgen deprivation therapy alone can lead to 
a strong selection pressure for the evolution of CRPC, co-treatment with a glycolysis or 
HK II inhibitor may help to inhibit metabolic adaptation to the androgen independent 
milieu.  In this study we have demonstrated that increased HK II and its association with 
the mitochondria likely afford both a metabolic and pro-survival benefit to prostate 
cancer cell survival in androgen deprived conditions.  Thus improved treatments for 
CRPC may require not only targeting relevant cell signaling pathways, but targeting 
metabolic adaptations as well.          
V. Materials and Methods 
 
Cell Culture and Orthotopic Transplantation  







 mice and were injected into the anterior prostate of nude mice as 
described in Chapter 2 methods [40].  Briefly, mice were anesthetized with isoflurane and 
castrated through an abdominal incision, followed by orthotopic injection of 5 x 10
5
 cells 
in 10ul, and implantation of a 5mg or 12.5mg subcutaneous testosterone pellet 
(Innovative Research of America, Sarasota, FL). Orthotopically injected nude mice were 
manually palpated weekly and removed from study upon signs of morbidity and/or when 
distended urinary bladders (indicative of urinary obstruction by prostate tumors) were 
easily palpable.  For the high dose 12.5mg DHT experiment mice were randomized into 
two groups at week four post orthotopic injection.  One group (n=9) had the 
subcutaneous testosterone pellets removed to simulate castration and allow for androgen 
independent tumor growth, while the other group (n=9) remained under the influence of 
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the testosterone pellet.  For the low dose 5mg DHT experiment mice were randomized 
into two groups at week 7 post orthotopic injection as described in Chapter 2 methods. 
Cell culture conditions were as described in Chapter 2 methods. 
Histology  
Orthotopic tumors were harvested and fixed with 4% paraformaldehyde 
overnight, rinsed well in PBS, and transferred to 70% ethanol prior to standard 
histological processing, sectioning and staining (Histoserve Inc., Germantown, MD).  All 
prostates and orthotopic tumors were sectioned as described (Shappell, et. al., 2004) 
allowing for the examination of all prostatic lobes, the seminal vesicles, bladder, and 
urethra.  Several sections of the tumor, two sections through each lung lobe, and the 
sublumbar lymph nodes were placed together on the same slide.  For the purpose of 
histopathological analysis of disease progression, for each mouse, two H&E sections 
separated by 200 um were analyzed.  For the purposes of imunophenotyping the lesions, 
sequential serial sections were used for all immunohistochemical staining.  Two serial 
sections (separated by 200 um) of the liver, kidneys, spleen, brain, head, and decalcified 
longitudinal sections of the lumbar spine as well as fore and hind limbs were analyzed 
from each animal to assay for metastasis.  All slides were analyzed blindly and 
histopathological analysis was done by a board certified veterinary pathologist (P. 
Martin). To quantify the percentage of orthotopic tumor area with a certain histological 
pattern, the area was estimated by using the number of 200X fields comprised by the 
particular histological pattern/total 200X fields analyzed, averaged over the two 200 um 
step sections. Bright field images were taken using an upright Zeiss Axioplan 




Unstained slides were deparaffinized, and antigen retrieval was performed in a 
citrate buffer (DAKO targeted antigen retrieval solution) in a steamer at 100°C for 15 
min, followed by a 15 min incubation at room temperature.  Blocking was performed 
with Cyto Q Background Buster reagent (Innovex Biosciences, Richmond, CA) for 30 
min at room temperature for rabbit primary antibodies, and for 1hr for mouse primary 
antibodies.  Primary antibody incubation was performed overnight at 4°C, followed by 
secondary antibody incubation at room temperature for 30 min. Secondary goat anti-
rabbit biotinylated IgG (E0432), and goat anti-mouse biotinylated IgG (E0433), used at 
1:200 dilution were from Dako (Carpinteria, CA).  The ABC peroxidase kit (Vector 
Laboratories, Burlingame, CA) was used followed by DAB (Dako) for chromogen 
visualization, and ImmPACT NovaRED (Vector Laboratories). All slides were 
counterstained with hematoxylin.   Primary antibodies and the concentrations used are as 
follows.  The following primary antibodies were obtained from Abcam (Cambridge, 
MA): anti-Ki-67 (ab15580), 1/600; anti-CK8 (ab59400), 1:50; anti-synaptophysin 
(ab52636), 1:250; anti-Chromogranin A (ab15160), 1:10,000; and anti-PTEN (ab9559), 
1:100. Additional antibodies were anti-CK5, 1:1000, from Covance (PRB-160P),San 
Diego, CA; anti-TP63, 1:400, from Millipore (MAB4135), Billerica, MA; anti-AR (sc-
816), 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA. The following antibodies 
were obtained from Cell Signaling (Danvers, MA): anti-E-cadherin (3195), 1:100; anti-





Dual Color Immunohistochemistry 
For dual color IHC to detect nuclear Ki67 in proliferating cells and cytoplasmic 
HK II, a sequential staining protocol was used for the two rabbit antibodies. 
First slides were immunostained for Ki67 as described above, with a one hour primary 
incubation, followed by the standard Vector ABC IHC protocol with detection using 
ImmPACT NovaRED for 40 minutes.  Slides were then washed for 5 minutes in PBST 
and then blocked with Cyto Q Background Buster for 20 minutes.  Anti-Hexokinase II 
antibody was then applied and incubated overnight (approximately 12-16hrs) at 4C.  
Routine Vector ABC IHC protocol was used with DAB detection for 25 minutes.  
For manual scoring of per cell HK II levels the slides were scanned with the 
Aperio™ system at 20x.  Images were captured at 20X that comprised the entire tumor 
area.  100 Ki67+ were scored followed by 100 Ki67- cells.  Each cell was scored 
according to this semi-quantitative scoring system: 0=negative, 1=minimal/mild labeling; 
2=moderate labeling; 3=strong labeling.  Data was analyzed using Graph Pad Prizm™, 
using T-test for statistical comparison of group means. 
For automated detection using the Ariol™ scanning/analysis platform the slides 
were first scanned at 20X.  The entire tumor region for each mouse was divided into 
equal 150um square regions of interest (ROI).  Using the multi-stain assay the following 
features were counted for each ROI using the color and size parameters: number of 
positive Ki67 nuclei, number of negative hematoxylin counter stained nuclei, and % area 
positive for HK II DAB+ cytoplasm.  For each ROI the % nuclei positive for Ki67 and 
the % area positive for HK II were plotted and analyzed using Graph Pad Prizm™.  
 105 
 
Linear regression analysis was used to compare the slopes of the two linear equations 
describing the relationship between proliferation and %area + for HK II.  
Reverse Transcriptase PCR   
The Qiagen™ (Glucose Metabolism RT-PCR array was used to analyze the expression of 
84 genes involved in glucose/TCA/glycogen/gluconeogenesis/and pentose phosphate 
pathway metabolism.  In addition, separate RT-PCR reactions were performed using 
Qiagen RT-PCR assay primers for GLUT1, GLUT4, CPTa, CPTb, and PRL.  For reverse 
transcription, 3ug of total RNA was used with the SuperScript III kit (Invitrogen, 
Carlsbad, CA).  The amplification step used the SYBR green PCR master mix (Applied 
Biosystems, Bedford, MA).   For all primer pairs, the thermocycler was run for 40 cycles 
with an initial 95°C incubation for 10 minutes, followed by 95°C melting  for 15 seconds, 
55°C annealing  for 30 seconds, and 72°C extension for 30 seconds. 
Western Blotting 
For protein detection, the following primary antibodies at the indicated concentrations 
were used in an overnight 4C incubation: anti-rabbit CK8 (Abcam, ab59400), 1/1000; 
anti-rabbit AR (Millipore, #06-680), anti-rabbit AR (Epitomics) , 1/500; anti-rabbit p-
AKT (Cell Signaling, #4060), 1/1000;  anti-rabbit AKT (Cell Signaling, #4691), 1/1000; 
anti-mouse TP63 (Millipore, NAB-4315), 1/500; anti-mouse GAPDH (Novus 
Biochemicals, Littleton, CO: NB300-221), 1/4000.  Secondary antibodies (1:2000) were 
anti-rabbit IgG (#386325) or anti-mouse IgG (#381254) (GE Healthcare, Piscataway, 
NJ), incubated at room temperature for 1 hour.  
For detection of metabolism enzymes the following primary antibodies at the 
indicated concentrations were used in an overnight 4C incubation: anti-mouse pyruvate 
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dehydrogenase E1a subunit (Abcam, Ab110334), 1/1000; anti-rabbit Aco1-cytoplasmic 
aconitase (Abcam, Ab126595); anti-rabbit Aco2-mitochondrial aconitase (Abcam, 
ab71440); anti-rabbit Aco2 (Kindly donated by Tracey Roualt); anti-rabbit Glutaminase 
(Abcam, ab93434); anti-rabbit Phosphofructokinase-1 (Abcam, ab37583). 
Metabolomics 
Flash frozen samples of each tumor were analyzed for global metabolite expression as 
described previously using mass spectroscopy (Metabolon™).  All biochemical 
quantifications and bioinformatics analysis of metabolite changes were done by 
Metabolon™. 
Enzyme Activity Assays 
The enzyme activities of hexokinase and pyruvate dehydrogenase enzymes were 
determined using the hexokinase enzyme assay kit (E-111) and the Pyruvate 
dehydrogenase assay kit (E-109) from Biomedical Research Service and Clinical 
Application. University of Buffalo: http://www.bmrservice.com/index.html. Briefly flash 
frozen tumor sections were pulverized in glass dounce homogenizers under dry ice, prior 
to addition of ice cold lysis buffer.  Tumor samples were homogenized with 10 strokes of 
the homogenizer and then lysates were transferred to 1.5ml Eppendorf tubes on ice.  
After following procedure detailed in enzyme assay kit, protein concentrations of lysates 





Chapter 4: Conclusion 
This dissertation research has succeeded in meeting its two major aims: 
1) Develop and characterize a mouse model of Pten/Tp53 deleted prostate cancer to 
investigate: the innate presence of castrate resistant prostate cancer (CRPC), the 
identity of tumor and metastasis initiating cells, and the lineage specific 
development of epithelial-to-mesenchymal transition.    
Hypothesis: Orthotopically injected Pten and Tp53 mouse prostate carcinoma 
will be capable of androgen independent (castrate resistant) growth and 
metastasis.  The phenotypic heterogeneity: adenocarcinoma, adenosquamous 
carcinoma, basal/squamous carcinoma, and sarcomatoid carcinoma, each with 
occasional neuroendocrine differentiation, that are observed in primary tumors 
and metastases are due to a multi-potent tumor and metastasis initiating prostate 
progenitor cell that is capable of differentiating along basal and luminal lineages 
with occasional neuroendocrine differentiation.  
Summary and Significance: By using a clonal cell line to produce orthotopic 
tumors with the full range of heterogeneity that was observed in the original 
genetically engineered mouse tumors, we confirmed that Pten/Tp53 loss in the 
prostate epithelium can transform multipotential progenitor cells with a tumor and 
metastasis initiating capability of differentiating along each of the prostate 
epithelial lineages: luminal and basal, with occasional neuroendocrine marker 
expression.  In addition, we show that Pten/Tp53 loss leads to epithelial-to-
mesenchymal transition in cells of the luminal lineage.  The significance of these 
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findings is in defining two distinct tumor initiating cells which we used to 
produce clonal cell lines with different lineage differentiation potential, one 
capable of basal and/or luminal differentiation, and the other a luminal progenitor 
with EMT.  Both of these clonal tumor initiating cell lines were capable of 
producing prostate adenocarcinoma that is similar in histological appearance and 
cytokeratin expression to most common human adenocarcinomas (CK8/18+, with 
occasional synaptophysin+ cells).  We also provide an accurate and thorough 
characterization of a widely used mouse model of human prostate cancer. 
2) Determine if there are metabolic differences between androgen dependent and 
castrate resistant prostate cancer that may serve as adaptations for the evolution 
and survival of CRPC.   
Hypothesis: CRPC will be associated with increased glycolysis as an adaptation 
to survival in androgen independent conditions in contrast to the reliance on lipid 
metabolism in androgen replete conditions.  This increased glycolysis is adaptive 
not only to compensate for energetic needs, but also to provide carbon precursors 
for anabolic processes such as lipogenesis and nucleic acid synthesis via the 
Pentose phosphate pathway, as well as to prevent metabolic stress induced 
apoptosis. 
Summary and Significance:  The discovery of the adaptive mechanism of 
increased cytoplasmic and mitochondrial associated hexokinase II in promoting 
prostate cancer progression to androgen independent growth is a novel finding 
that may help to develop new and improved treatment strategies for CRPC.  
Although this mechanism has been demonstrated to occur in carcinogenesis in 
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several tumor types, we are the first to demonstrate its role in androgen 
independent prostate cancer.  The findings in our genotype specific mouse model 
mirrored the findings in human prostate cancer specimens which came from 
diverse genetic backgrounds.  This suggests that we have identified a unifying 
metabolic mechanism that plays a significant role in the development of 
aggressive and/or androgen independent prostate carcinoma regardless of 
genotype.  The mechanism of HK II binding to the outer mitochondrial membrane 
Voltage dependent Anion Channel (VDAC) provides an important pro-survival 
mechanism by blocking the binding of pro-apoptotic factors.   
Our findings suggest that the significance of the increased phosphorylation 
of glucose afforded by the higher ATP supply from the outer mitochondrial anion 
exchange channel, that HK II can access when attached to the VDAC, not only 
increases energy production, but also provides increased carbon precursors for 
critical anabolic pathways: lipogenesis via shuttling of citrate back into the 
cytoplasm, and nucleic acid production via the pentose phosphate pathway.  Our 
metabolic data also suggests that the androgen independent tumors can 
compensate for this loss of citrate for lipogenesis, by the anaplerotic reactions of 
glutaminolysis and aspartate conversion to oxaloacetate.   
This study provides a new mechanistic understanding of the metabolic 
changes associated with the development of androgen independent prostate cancer 
and provides new targets for treatment of CRPC.  The research presented in this 
work affirms the importance and relevance of using mouse models of human 
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